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Preclinical neuroscience research presents contradictory evidence in support of 
both protective and destructive effects of cannabinoids in the context of chronic 
unpredictable stress. Cannabis, one of the most commonly abused drugs, affects the 
hypothalamic pituitary adrenal axis stress response, similarly to other drugs of abuse. 
Compared to other drugs of abuse, cannabis primarily interacts with the endogenous 
cannabinoid system. The endogenous cannabinoid system has been recently identified to 
facilitate both activation and termination of the hypothalamic pituitary adrenal axis stress 
response. This systematic review and meta-analysis summarizes the existing preclinical 
literature on the effects of cannabinoid administration in the chronic unpredictable stress 
model of depression. Scopus, Embase, Psychology & Behavioral Sciences Collection, 
APA PsychINFO, PubMed, CINAHL Complete, and ProQuest Dissertations & Theses 
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Global were systematically searched for articles that met inclusion criteria and the 
standardized mean differences were calculated for each continuous behavioral measure 
between vehicle chronic unpredictable stress groups and cannabinoid-treated chronic 
unpredictable stress groups. The overall effect of cannabinoids on depressive-like 
behavior was evaluated using a multi-level mixed effects model with effect size weights 
nested within control groups to address dependency between measurements compared to 
same control group. A total of 26 preclinical articles were included. Overall, cannabinoid 
administration rescued the negative effects of chronic unpredictable stress on anhedonia, 
learned helplessness, novelty suppressed feeding, and exploration anxiety with a pooled 
standardized mean difference of 0.4456 (95% CI 0.0498 – 0.8415, p = 0.0274). 
Moderator analyses revealed that this effect significantly increased with an increasing 
number of cannabinoid administrations and doses. Furthermore, this effect was 
significantly greater in mice, with cannabinoids that enhances the endogenous 
cannabinoid system, with cannabinoid treatments that are not co-treatments, and when 
the cannabinoid is administered during chronic unpredictable stress. These findings 
suggest that cannabinoids may be a viable treatment for stress-related psychopathologies 
but further investigation is needed into the sample characteristics where cannabinoids are 
more efficacious in order to properly assess the benefits of cannabinoid-based 
pharmacotherapies.  
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 It is unclear if cannabis helps individuals cope with life’s stressors or increases 
the likelihood of developing stress-related disorders such as depression. Chronic 
unpredictable stress is a validated model of depression that exposes rodents to a series of 
frequently-occurring, intermittent stressors over the course of a few weeks. This 
systematic review and meta-analysis summarizes existing research using rodents on the 
effects of cannabinoids on stress-coping behaviors and neuroendocrinological 
measurements in chronic unpredictable stress. Databases were systematically searched 
for articles that met inclusion criteria, and effect sizes between control chronic 
unpredictable stress groups and cannabinoid-treated chronic unpredictable stress groups 
were calculated. A meta-analysis of the 26 included articles indicated that cannabinoids 
prevent the negative effects of chronic unpredictable stress, suggesting that the 
development of cannabinoid-based drugs has the potential to treat stress-related disorders 
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 According to the World Health Organization, “depression is a leading cause of 
disability worldwide” ("Depression," 2020). Depression can lead to suicide, which is the 
“second leading cause of death in 15-29-years-olds” ("Depression," 2020). Furthermore, 
the global impact of depression and related disorders continue to increase ("Depression," 
2020). Current antidepressants have therapeutic delays, low efficacy, and increased risk 
of suicide indicating a need for alternative pharmacotherapies for depression (Fang & 
Wang, 2018; Xu et al., 2019). 
 Mounting preclinical evidence suggests that pharmacological enhancement of the 
endogenous cannabinoid system (ECS) promotes antidepressant and anxiolytic effects 
(Bortolato et al., 2007; Campos et al., 2013; Fogaça, Campos, Coelho, Duman, & 
Guimarães, 2018; Gáll et al., 2020; García-Gutiérrez, Pérez-Ortiz, Gutiérrez-Adán, & 
Manzanares, 2010; Hwang et al., 2020; Jankovic, Spasojevic, Ferizovic, Stefanovic, & 
Dronjak, 2020; Jin, Yu, Tian, Zhang, & Quan, 2015; Segev, Rubin, Abush, Richter-
Levin, & Akirav, 2014; H.-n. Wang et al., 2014; Xu et al., 2019; Zhang et al., 2015; 
Zhong et al., 2014). Clinically, cannabis is the most commonly abused illicit drug 
worldwide, due to reported effects on relaxation and well-being (Volkow, Hampson, & 
Baler, 2017). However, chronic cannabis use appears to dysregulate the hypothalamic-
pituitary-adrenal (HPA) axis, thereby increasing the likelihood of developing stress-
related psychopathologies such as depression (Hillard, Beatka, & Sarvaideo, 2018; 
McEwen, 2003).  
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Aims 
 This research aims to identify the conditions in which exogenous administration 
of cannabinoids (CBs) promotes stress vulnerability (thereby increasing the likelihood of 
developing stress-related psychopathologies such as depression) and the conditions in 
which exogenous administration of CBs promote stress resilience (to advance the 
development of pharmacotherapies for stress-related psychopathologies). A preclinical 
meta-analysis poses a unique benefit in comprehensively organizing existing evidence. 
Moderator analyses can identify characteristics which influence the overall effect of CBs 
in chronic unpredictable stress (CUS) and sources of between study heterogeneity in 
effect sizes. Identification of significant moderators can provide guidance for the 
experimental design of future preclinical studies (Vesterinen et al., 2014). The purpose of 
this guidance is to facilitate the development of CB-based pharmacotherapies by 
identifying gaps in the literature, encouraging preclinical research designs with greater 
external validity, and discouraging unnecessary preclinical research designs (Leenaars et 













Stress and The Hypothalamic Pituitary Adrenal Axis 
 Life is full of stressors or stimuli which are perceived as threats (Franklin, Saab, 
& Mansuy, 2012). These stressors, whether they are physical or psychological, provoke 
evolutionarily conserved physiological responses such as the sympatho-adrenomedullary 
and HPA axes (Ulrich-Lai & Herman, 2009). This thesis focuses on unpredictable 
psychological stressors and the HPA axis: the neuroendocrinological response involved 
in chronic stress (Ulrich-Lai & Herman, 2009). 
 Stress reactivity varies between individuals (Franklin et al., 2012). Stress resilient 
individuals demonstrate adaptive responses to stress referred to as allostasis (Franklin et 
al., 2012; McEwen, 2003; Ulrich-Lai & Herman, 2009). In contrast to stress resilient 
individuals, stress vulnerable individuals are susceptible to allostatic overload or a “wear 
and tear” of their stress response, thereby increasing the likelihood of developing a wide 
variety of stress-related psychopathologies such as anxiety, post-traumatic stress disorder, 
and substance use disorder (Franklin et al., 2012; McEwen, 2003; Ulrich-Lai & Herman, 
2009). This thesis will exclusively focus on major depressive disorder (MDD) because it 
is modeled in laboratory rodents by the CUS paradigm (Franklin et al., 2012; Katz, 1982; 
P. Willner, Towell, Sampson, & Sophokleous, 1987).  
 In order to effectively treat stress-related psychopathologies such as MDD, it is 
imperative to elucidate the etiology of stress resilience and stress vulnerability (Franklin 
et al., 2012). According to the stress inoculation model, acute early-life stress can 
promote stress resilience (Franklin et al., 2012). This acute stress is beneficial because it 
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teaches the individual to actively cope with the stress by problem solving or by seeking 
social support (Franklin et al., 2012). In contrast, there is a correlation between childhood 
maltreatment and the likelihood of developing stress-related psychopathologies later in 
life (Franklin et al., 2012). Severe early-life stress teaches individuals to passively cope 
with stressors by avoiding conflict and disengaging behaviorally, characteristics which 
are observed in MDD (Franklin et al., 2012). The severity of a stressor depends upon its 
predictability, since unpredictable stressors are harder to control and circumvent 
(Franklin et al., 2012). In addition to predictability, the frequency and duration of stress 
contributes to a shift from allostasis to allosteric overload (Franklin et al., 2012; 
McEwen, 2003). 
To effectively model chronic and unpredictable stress, the CUS paradigm exposes 
rodents to a variety of frequently-occurring, intermittent stressors, for several weeks 
(Franklin et al., 2012). CUS induces passive-coping behaviors such as learned 
helplessness (e.g. increased immobility in the Porsolt forced swim test) and anhedonia 
(i.e. reduced interest in sweetened water) that reflects the diagnostic criteria of MDD 
(Franklin et al., 2012; Porsolt, Le Pichon, & Jalfre, 1977). The CUS paradigm was 
originally proposed by Richard Katz (Katz, 1982). Then the CUS model was validated by 
Willner and colleagues, who showed that CUS-induced anhedonia could be reversed with 
chronic (but not acute) antidepressant treatment (Bortolato et al., 2007; Paul Willner, 
1984; P. Willner et al., 1987). This result demonstrated the paradigm’s high predictive 
validity (Bortolato et al., 2007; Paul Willner, 1984; P. Willner et al., 1987).  
In support of the predictive validity of this model, stimulants, which can result in 
false positives for acute stress models of depression, do not reverse depressive symptoms 
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in CUS (Bortolato et al., 2007). This paradigm also has high construct validity because 
rodents can either demonstrate active-coping behaviors such as exploratory activity or 
passive-coping behaviors such as learned helplessness (Franklin et al., 2012; Paul 
Willner, 1984). Additionally, this paradigm has high face validity demonstrated in 
chronic elevations of the stress hormone corticosterone (CORT) or cortisol observed in 
both rodents and MDD patients, respectively (Franklin et al., 2012; McEwen, 2003; Paul 
Willner, 1984).  
Contributing to the face validity of the paradigm, CUS also results in variability in 
responses, which is comparable to how humans differently respond to stressors (Franklin 
et al., 2012). Furthermore, there are strain differences in stress reactivity with BALB/c 
mice being considered stress vulnerable, C57BL/6J mice being considered stress resilient, 
and CD1 mice demonstrating more variability in stress reactivity (Franklin et al., 2012). 
Most importantly, rodents exposed to CUS demonstrate sexual dimorphisms in HPA axis 
activity, which accurately reflect the increased prevalence of stress-related 
psychopathologies in females compared to males when investigating the 
neuroendocrinology of stress (Franklin et al., 2012).  
 The neuroendocrinology of stress encompasses a wide variety of 
neurotransmitters, neuromodulators, neurotrophic factors, neuropeptides, and hormones 
that are beyond the scope of this thesis, which aims to provide a generalized introduction 
to the HPA axis (Franklin et al., 2012; Ulrich-Lai & Herman, 2009). Prior to HPA axis 
activation, limbic stress circuits consisting of the prefrontal cortex (PFC), hippocampus, 
and amygdala are involved in the regulation of stress (Ulrich-Lai & Herman, 2009). 
These stress excitatory circuits and stress inhibitory circuits overlap with regions such as 
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the bed of the nucleus stria terminalis (BNST) to integrate information regarding the 
stressor (Ulrich-Lai & Herman, 2009). The PFC is likely the principle coordinator of 
psychological reactivity to stress (Ulrich-Lai & Herman, 2009). In the rodent brain, the 
PFC is composed of the prelimbic cortex (PrL) and infralimbic cortex (IL) which both 
relay to regions such as the basolateral amygdala (BLA), resulting in overall inhibitory 
and excitatory effects of the HPA axis, respectively (Ulrich-Lai & Herman, 2009). The 
BLA relays through the BNST to provoke activation of the HPA axis (Ulrich-Lai & 
Herman, 2009). In contrast, the ventral subiculum of the hippocampus is the main region 
inhibiting the activation of the HPA axis (Ulrich-Lai & Herman, 2009).  
Ultimately, HPA axis activation begins with the paraventricular nucleus of the 
hypothalamus (PVN) secreting corticotropin-releasing hormone (CRH) into the portal 
vein (Franklin et al., 2012; Ulrich-Lai & Herman, 2009). CRH binds to CRH receptor 1 
(CRHR1) in the anterior pituitary to secrete adrenocorticotropic hormone (ACTH) into 
the bloodstream (Ulrich-Lai & Herman, 2009). ACTH binds to receptors on the zona 
fasciculate of the adrenal cortex, causing the secretion of glucocorticoids (GC) (i.e. 
CORT) (Ulrich-Lai & Herman, 2009). These GC initiate negative feedback of the HPA 
axis, thereby terminating HPA axis activity by binding to GC receptors (GRs) in regions 
such as the hypothalamus, hippocampus, amygdala, and PFC (Franklin et al., 2012; 
Hillard et al., 2018; Ulrich-Lai & Herman, 2009). Regions such as the hippocampus are 
in turn affected by GCs (Franklin et al., 2012). High circulating levels of GCs in 
instances of chronic stress can decrease GR expression and increase dendritic atrophy, 
thereby contributing to the reduction of hippocampal volume observed in MDD (Franklin 
et al., 2012; Ulrich-Lai & Herman, 2009).  
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The Endogenous Cannabinoid System and Cannabinoids 
The fundamental elements of the ECS consists of the cannabinoid one receptor 
(CB1R), the cannabinoid two receptor (CB2R), the endogenous cannabinoid (eCB) 
arachidonoyl-ethanolamide (i.e. anandamide) (AEA), the eCB 2-arachidonoyl glycerol 
(2-AG), and the enzymes involved in eCB synthesis and catabolism (Lu & Mackie, 
2016). eCBs are called retrograde messengers because their synthesis and immediate 
diffusion from the postsynaptic membrane via enzymatic reactions contrasts classical 
exocytosis of synaptic vesicles (containing pre-synthesized neurotransmitters) from the 
presynaptic membrane (Lu & Mackie, 2016). 
CB1R and CB2R are !!/# type G-protein coupled receptors (GPCRs) which 
inhibit adenylyl cyclase (AC), inhibit calcium channels, activate mitogen-activated 
protein kinase (MAPK), and activate potassium channels, thereby preventing 
depolarization and neurotransmitter release (Lu & Mackie, 2016). CB1R is the most 
abundant GPCR in the central nervous system, especially in the hippocampus, cortex, 
basal ganglia, and cerebellum (Lu & Mackie, 2016; Volkow et al., 2017). CB1Rs are 
typically located on presynaptic membranes on inhibitory GABAergic neurons (such as 
medium spiny neurons) but are also present on excitatory glutamatergic neurons (Lu & 
Mackie, 2016). In comparison, CB2Rs are typically located on immune cells such as 
microglia and endothelial cells, with increasing expression in response to inflammation 
(Hillard et al., 2018; Lu & Mackie, 2016). Beyond the fundamental cannabinoid (CB) 
receptors, several subtypes of transient receptor potential (TRP) channels, nuclear 
receptors such as peroxisome proliferator activated receptors (PPARs), orphan GPCRs, 
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and more are activated by eCBs (Lu & Mackie, 2016; Morales & Reggio, 2019). The role 
of these receptors in the extended ECS remains as a topic of on ongoing investigation.  
 The ECS modulates synaptic transmission throughout the brain. In synapses, eCB 
phospholipid precursors are present on the lipid membrane of the postsynaptic neuron in 
order to be released on demand in response to !$ GPC activation and/or depolarization 
(Hillard et al., 2018; Lu & Mackie, 2016). The synthesis and release of eCBs mediates 
short-term plasticity regarded as metabotropic-induced suppression and depolarization-
induced suppression of inhibition or excitation, respectively (depending on the location of 
the CB1R on the presynaptic neuron) (Lu & Mackie, 2016). Phospholipase C (PLC), 
which can be activated by !$ GPCs, is also sensitive to intracellular calcium, acting as a 
coincidence detector to synthesize eCBs (Hillard et al., 2018; Lu & Mackie, 2016). While 
PLC is involved in eCB mediated short-term plasticity, the mechanism for eCB mediated 
long-term plasticity involves the inhibition of AC (Lu & Mackie, 2016). 
To facilitate eCB mediated synaptic plasticity, there are a variety of synthesis 
pathways for both eCBs (Lu & Mackie, 2016). The best understood AEA synthesis 
pathway involves the cleavage of the N-arachidonoyl phosphatidyl ethanol’s (NAPE) 
phosphodiester bond by NAPE PLC, thereby removing a diacylglycerol (DAG) group to 
produce phospho-AEA (Lu & Mackie, 2016). The phospho-AEA becomes 
dephosphorylated by a phosphatase to synthesize and release AEA (Lu & Mackie, 2016). 
In comparison to AEA, the main synthesis pathway for 2-AG begins with the hydrolysis 
of arachidonoyl-containing phosphatidyl inositol bis-phosphate by PLC", thereby 
removing inositol trisphosphate (Lu & Mackie, 2016). A second hydrolysis reaction of 
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the DAG group by the enzyme diacylglycerol lipase (DAGL), removes a carboxyl group 
to synthesize and release 2-AG (Lu & Mackie, 2016).  
 Once the eCBs are synthesized, both AEA and 2-AG can be catabolized by 
cyclooxygenase-2 (COX-2) or fatty acid amide hydrolase (FAAH) (Lu & Mackie, 2016). 
FAAH metabolizes various fatty acid amides, such as eCBs palmitoyl-ethanolamide 
(PEA) and oleoyl-ethanolamide (OEA) (Lu & Mackie, 2016). Overall, the main catabolic 
enzyme for AEA is FAAH, while the main catabolic enzyme for 2-AG is 
monoacylglycerol lipase (MAGL) (Lu & Mackie, 2016). The enzymes involved in AEA 
and 2-AG synthesis and catabolism are predominantly located in complementary neurons 
in synapses (Hillard et al., 2018; Lu & Mackie, 2016; Morena, Patel, Bains, & Hill, 
2016). AEA synthesis is facilitated by NAPE-PLD in presynaptic neurons and AEA 
catabolism is facilitated by FAAH in postsynaptic neurons (Hillard et al., 2018; Lu & 
Mackie, 2016; Morena et al., 2016). In comparison to AEA, 2-AG synthesis is facilitated 
by DAGL in postsynaptic neurons and 2-AG catabolism is facilitated by MAGL in 
presynaptic neurons (Hillard et al., 2018; Lu & Mackie, 2016; Morena et al., 2016). 
These differences in enzyme locations in synapses contribute to AEA and 2-AG’s 
complimentary functions in signaling (Hillard et al., 2018; Lu & Mackie, 2016; Morena 
et al., 2016). 
 In addition to being synthesized and catabolized in opposite locations in synapses, 
AEA and 2-AG have different pharmacodynamic effects on the CB receptors (Hillard et 
al., 2018; Lu & Mackie, 2016; Morena et al., 2016). AEA has low efficacy for CB 
receptors, so it is considered to be involved in tonic eCB signaling, while 2-AG has high 
efficacy for CB receptors to facilitate phasic eCB signaling (Hillard et al., 2018; Lu & 
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Mackie, 2016; Volkow et al., 2017). AEA also activates TRP channels and PPARs 
(Hillard et al., 2018; Lu & Mackie, 2016). The lower efficacy of AEA constitutes it as a 
partial agonist similarly to tetrahydrocannabinol (THC), a compound attributed to the 
intoxicating effects cannabis (Volkow et al., 2017). Cannabidiol (CBD), is another well-
researched phytocannabinoid (i.e. from the cannabis plant) with non-psychoactive effects 
(Morales & Reggio, 2019). CBD’s receptor pharmacology is complex (Morales & 
Reggio, 2019). Functionally, CBD has been considered as an antagonist for CB receptors, 
but recent research suggests that CBD could be a negative allosteric modulator (Morales 
& Reggio, 2019). Furthermore, CBD inhibits FAAH, targets TRP channels, PPARs, and 
many more targets whose functions have yet to be elucidated (Morales & Reggio, 2019). 
Another relevant phytocannabinoid is "-Caryophyllene (BCP) which is a CB2R agonist 
that is being investigated because of its anti-inflammatory effects (Hwang et al., 2020). 
 Like the wide variety of naturally occurring CB compounds, there are even more 
synthetic CB compounds. One of the most infamous synthetic CBs is rimonabant (RIM), 
which is a CB1R antagonist with inverse agonist effects when chronically administered 
(Fang & Wang, 2018). Originally marketed for obesity, RIM was withdrawn in 2008 due 
to psychiatric effects such as anxiety and suicidal ideation (Cinar, Iyer, & Kunos, 2020). 
This instance was a grave lesson in understanding the direct relationship between CB1Rs 
and mood in humans. Fortunately, the promising anti-obesity results in these trials has led 
to the continuation of this research and current development of peripherally-restricted 
CB1R antagonists for these metabolic disorders (Cinar et al., 2020). AM251, which is 
structurally and pharmacologically similar to RIM, is another synthetic CB that is 
frequently administered in preclinical behavioral experiments to block CB1R activity 
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(Fang & Wang, 2018; Fogaça et al., 2018; McLaughlin et al., 2013; Pekala, Michalak, 
Kruk-Slomka, Budzynska, & Biala, 2018; H.-n. Wang et al., 2014). Similarly, AM630, a 
CB2R antagonist and inverse agonist, is used in preclinical behavioral experiments to 
block CB2R activity (Fogaça et al., 2018; García-Gutiérrez et al., 2010; Ishiguro et al., 
2018).  
 Since THC is a Schedule I substance, a variety of synthetic CBs have been 
developed to research the ECS (Leonhart, 2010). Commonly-researched, synthetic CBs 
include WIN55,212-2, a CB1R and CB2R agonist, and HU-210, a potent non-selective 
CB1R agonist (Hill & Gorzalka, 2004; Segev et al., 2014). More selective synthetic CBs 
include, arachidonyl-2-chloro-ethylamide (ACEA), which is administered for CB1R 
agonism, or JWH133 and JWH015, which are administered for CB2R agonism (Ishiguro 
et al., 2018; S. Wang et al., 2016). In addition to targeting CB receptors, compounds 
inhibiting catabolic enzymes FAAH and MAGL, which is intended to increase levels of 
AEA and 2-AG respectively, have demonstrated greater clinical potential because they 
increase CB signaling while circumventing receptor downregulation (Volkow et al., 
2017). The most popularly researched enzyme inhibitors are URB597 and JZL184 for 
FAAH and MAGL, respectively (Ferizovic, Spasojevic, Stefanovic, Jankovic, & 
Dronjak, 2020; Jankovic et al., 2020; Lomazzo et al., 2015; Lomazzo, Konig, Abassi, 
Jelinek, & Lutz, 2017; Zhang et al., 2015; Zhong et al., 2014). Unfortunately, the clinical 
development FAAH inhibitors was halted in 2016 due to a fatal phase I trial involving an 
FAAH inhibiter called BIA 10-2474 (Volkow et al., 2017). The food and drug 
administration safety review stated that the toxicity of BIA 10-2474 is unique to this 
FAAH inhibitor (Volkow et al., 2017). BIA 10-2474’s toxicity is likely due to having a 
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low affinity for FAAH thereby increasing the probability of off-target effects (Volkow et 
al., 2017). Fortunately, the clinically safer FAAH inhibitors PF-04457845 and JNJ-
42165279 have currently resumed recruitment of participants for clinical research 
(NCT03386487; NCT03664232). Although these compounds are being tested for a 
variety of disorders, a substantial amount of the clinical trials for efficacy are focused on 
stress-related psychopathologies.   
Stress-Induced Endocannabinoid Mobilization 
 Chronic cannabis use appears to dysregulate the HPA axis (Hillard et al., 2018). 
Therefore, it is possible that CBs can modulate the HPA axis (Hillard et al., 2018). 
Evidence that supports the role of the ECS in both activating and terminating the HPA 
axis begins with the expression of CB1R at all levels of the HPA axis (Hillard et al., 
2018). Hill and colleagues have hypothesized that AEA tonically inhibits the BLA by 
basal CB1R activation and that the release of CRH activates CRHR1 to increase FAAH 
activity, thereby reducing AEA levels to allow the BLA to facilitate activation of the 
HPA axis (Hillard et al., 2018). Furthermore, mounting evidence supports the hypothesis 
that GC release activates GR which mobilize the synthesis of eCBs to facilitate a rapid 
nongenomic mechanism for negative feedback of the HPA axis (Hillard et al., 2018). 
Although the specifics of this molecular mechanism has yet to be elucidated, evidence 
suggests that GR-mediated increases in calcium and PLC activity are involved (Hillard et 
al., 2018). In support of the GR-mobilization of eCB hypothesis, GC injections in the 
PVN suggest that the release of 2-AG activates CB1R to reduce glutamatergic input onto 
the PVN (Hillard et al., 2018). Additional evidence to support this hypothesis involve 
GR-mediated mobilization of 2-AG in the PFC and hippocampus (Hillard et al., 2018). 2-
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AG would activate CB1R to reduce GABAergic input into the PFC and hippocampus, 
thereby disinhibiting these regions in order to facilitate negative feedback of the HPA 
axis (Hillard et al., 2018). These hypotheses suggest that eCB signaling facilitates an 
adaptive stress response, demonstrated in the rapid and effective activation of the HPA 
axis followed by a timely and complete termination of the HPA axis (Franklin et al., 
2012; Hillard et al., 2018). Based on these hypotheses, researchers hope to invent novel 
pharmacotherapies that reliably enhance eCB signaling in order to regulate the HPA axis 
and protect against stress-related psychopathologies (Hillard et al., 2018). 
Statement of the Problem 
 Based on the role of the ECS in both activation and termination of the HPA axis, 
exogenous administration of CBs have the potential to both dysregulate and regulate the 
HPA axis (Hillard et al., 2018). The purpose of the present study is to better understand 
the conditions in which exogenous administration of CBs promote stress vulnerability 
and the conditions in which exogenous administration of CBs promote stress resilience 
with a systematic review and meta-analysis. Therefore, the proposed categorical 
moderators of this meta-analysis are species (rats vs. mice), sex (males vs. females), 
strain (control strain vs. disease model), method of administration (systemic vs. site-
specific), timing of administration relative to CUS (before vs. during vs. after), and 
overall effect on the ECS (enhancement vs. inhibition vs. neutral). The proposed 
continuous moderators are dose of the CB, number of administrations, and days of stress.  
 It is hypothesized that CBs would be most effective at promoting stress resilience 
in females and in disease models. The stress-resilient effects of CBs would be greatest in 
the most severe CUS models (i.e. with the longest duration). Furthermore, the most 
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efficacious CBs would be those that enhance the ECS when they are administered 
systemically at low doses during CUS. The stress-resilient effect of CBs would also be 
easier to sustain with CBs that target catabolic enzymes than with CBs that target CB 
receptors due to receptor regulation (i.e. tolerance). In contrast, high doses of CBs for 
short periods of time or chronic administration of CBs that inhibit the ECS are 





MATERIALS AND METHODS 
 
Overview 
This research adheres to the CAMRADES guidelines for conducting systematic 
reviews and meta-analysis of animal studies (Vesterinen et al., 2014). The preregistered 
research protocol in the Systematic Review Protocol for Animal Intervention Studies 
(SYRCLE) format is located in the appendix of this thesis (R. B. M. de Vries et al., 2015; 
Hooijmans et al., 2014). Duplicates of this protocol are publicly available in the 
Systematic Review Facility (SyRF) protocol database, PROSPERO protocol database 
(registration number: CRD42020219986), and on the Open Science Framework 
(https://osf.io/csgmf/) in order to facilitate visibility and transparency (R. B. M. de Vries 
et al., 2015). These resources were originally found in Reis, Casteen, and Ilardi’s 
preclinical systematic review and meta-analysis (Reis, Casteen, & Ilardi, 2019). 
Furthermore, additional resources to facilitate transparency were obtained from Moreau 
and Gamble and will be cited accordingly (Moreau & Gamble, 2020). 
Criteria 
Articles were deemed eligible for the meta-analysis if they met the following 
inclusion criteria: 1) study subjects were either rats or mice (R. B. de Vries, Hooijmans, 
Tillema, Leenaars, & Ritskes-Hoitinga, 2014; Hooijmans, Tillema, Leenaars, & Ritskes-
Hoitinga, 2010; Leenaars et al., 2012); 2) subjects received administration of a CB; 3) 
outcome measures included behavioral and/or neuroendocrinological stress; 4) subjects 
were exposed to variable heterotypic stressors for more than seven days; 5) there was a 
study matched control group; 6) the article was the primary source of the research (i.e. 
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not a review); 7) the article was available in English. Although this last criteria poses as 
an inherent bias against non-English articles, there appears to be minimal benefit in the 
translation of non-English articles (Jüni, Holenstein, Sterne, Bartlett, & Egger, 2002). 
Conference abstracts were omitted due to limited information. In the second stage of 
screening, the reason for removal of the article was documented and reported (Figure 1) 
in order facilitate transparency of the screening process (Leenaars et al., 2012). The 
inclusion criterion of “variable heterotypic stressors for more than seven days” was 
applied in the second stage of screening in order to prioritize severe and previously 
validated CUS paradigms. Protocol deviations such as these were documented and are 
located in the appendix of this thesis (Table 5). 
Search Strategy 
Potential articles were identified by searching Scopus, Embase, Psychology & 
Behavioral Sciences Collection, APA PsychINFO, PubMed, CINAHL Complete, and 
ProQuest Dissertations & Theses Global from the earliest record of the databases to 
November 2020. The libraries were imported into EndNote X9 and Mendeley for 
automatic then manual de-duplication which was replicated at least three separate times 
to ensure that no reference was deleted by accident. Search terms included rat OR mouse 
AND cannabinoids AND chronic stress. The complete search strategy including the exact 
search syntax used for each database is located in the appendix of this thesis (Table 6). 
All articles were screened and evaluated in a standardized manner by two independent 
reviewers (N.R. and C.C). First, the title and abstract for each reference was reviewed to 
identify potential articles before reviewing the full-text to determine article eligibility. 
Disagreements between reviewers were resolved by discussion and the final decision was 
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made by a third independent reviewer (S.F.). In included articles, citations were tracked 
both forwards and backwards to search for additional articles. Both forms of citation 
tracking did not result in additional included articles, indicating that there was no need 
for further citation tracking of excluded reviews. Authors of included studies, relevant 
investigators at the National Institute of Health, and at the Hebrew University 
Multidisciplinary Center on Cannabinoid Research were contacted for grey literature. In 
total, 53 authors were individually contacted for grey literature in efforts to include all 
relevant data. Thirteen of those 53 emails received a response, and two of those responses 
contained article suggestions that were later excluded. Finally, authors of included studies 
were contacted and asked to provide additional study details and data when needed. 
Twenty-nine additional emails were sent out to request additional information. Out of 
those 29 additional emails, two responded saying they did not have the requested 
information, one agreed to send their data but was unable to find it, and one researcher 
responded with a raw dataset that corresponded to an included article. This raw dataset 
was used for a validation analysis by comparing the raw dataset to data extracted by the 
two independent reviewers using the WebPlotDigitizer software (Rohatgi, 2017). After 
the validation analysis, the raw dataset was used for the meta-analysis instead of the 
reviewer-extracted data. An additional exploratory search was conducted based on article 
recommendations provided by the Mendeley reference manager software, which yielded 
36 additional articles that were later excluded. 
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Figure 1. Flowchart of the Selection of Articles. Adapted from Moreau, D., & Gamble, B. 
(2020, January 7). Conducting a Meta-Analysis in the Age of Open Science: Tools, Tips, 




Electronic Databases (n = 1,711)
Searching electronic databases (Psychology and Behavioral 
Sciences Collection (n = 20), APA PsychINFO (n = 285), 
CINAHL Complete (n = 42), PubMed (n = 534), SCOPUS (n = 
400), and EMBASE (n = 430)) using combinations of search 
terms relating to RATS OR MICE AND CANNABINOIDS AND 









Records After Duplicates Removed
(n = 714)
Criteria For Study Inclusion
Inclusion Criteria 
1. Article text available in English 
2. Subjects are rats or mice
3. Administration of a cannabinoid (e.g. WIN55,212-2)
4. Outcome data related to anxiety tests (e.g. Open Field test) or stress-coping behaviors (e.g. Self-Grooming) and/or 
accompanying biochemical data (e.g. related to the endogenous cannabinoid system or hypothalamic pituitary 
adrenal axis stress response)
5. Chronic Unpredictable Stress (i.e. variable stress is administered for more than seven days).













Abstracts Excluded (n = 490)
Full Text Articles Evaluated but Excluded (n = 188)
1. Article text available in English (n = 0)
2. Subjects are rats or mice (n = 11)
3. Administration of a cannabinoid (n = 10)
4. Outcome data (n = 14)
5. Chronic Stress (n – 75)
subChronic Unpredictable Stress (n = 18) 
subChronic Homotypic Stress (n = 27)
Chronic Homotypic Stress (n = 31)
6. Control group (n = 0)





Articles Included (n = 26)
35 Study Groups • 165 Effect Sizes
Other Sources (n = 9)
ProQuest Dissertations & Theses Global (n = 9), 
open call e-mail requests for unpublished data (n = 
0), forwards citation tracking using Google Scholar 
of Included Articles (n = 0) and backwards citation 
tracking of Included Articles (n = 0).
Full Text Articles Unobtainable (in English) (n = 2)
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Data Collection 
All coding was completed using an online custom REDCap form that was 
developed based on CAMRADES guidelines (Harris et al., 2009; Vesterinen et al., 2014). 
For a complete list of extracted data fields, the REDCap codebook file is attached to the 
publicly available registered protocol in the SyRF protocol database, PROSPERO 
protocol database (registration number: CRD42020219986), and on the Open Science 
Framework (https://osf.io/csgmf/). Extracted data included subject information (e.g. 
rodent species, strain, age, and model), housing information (e.g. temperature and 
humidity), intervention type (e.g. frequency of stressors, number of stressors, and 
disruption of circadian rhythm), injection information (e.g. method of administration, 
dosage, and timing relative to stress), drug preparation (e.g. solvent), CB pharmacology 
(e.g. target) as well as behavioral data (e.g. sucrose preference and forced swim 
immobility time). Neuroendocrinological data from the articles included in the meta-
analysis was collected for systematic review due to anticipated limitations in sample size. 
Data presented in graphical format was extracted using WebPlotDigitizer graph 
digitization software (Rohatgi, 2017). A validation analysis compared the raw dataset 
provided from the researcher that responded, to the data that was extracted by the two 
independent reviewers using the WebPlotDigitizer software (Rohatgi, 2017). The means 
of the extracted dataset were within 3% of the raw dataset, while the standard errors of 
the means of the extracted dataset were within 13% of the raw dataset. If the final group 
sizes were given in a range, then the lowest number within that range was collected for a 
conservative estimate. Twenty-one articles used the standard error of the means for the 
error bars in their figures, and one article used standard deviation. Therefore, the four 
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articles which did not specify their error bars were assumed to be standard error of the 
mean. Unfortunately, this limitation in reporting variance has been previously observed 
in preclinical research (Vesterinen et al., 2014). Finally, for studies with repeated 
measures, data was only collected for the last measurement. All forms of data collection 
were conducted by two independent reviewers (N.R. and C.C). Disagreements between 
reviewers on article characteristics and neuroendocrinological data were resolved by 
discussion, and the final decision was made by a third independent reviewer (S.F.). For 
the behavioral data, measurements that were not within half a unit of each other or within 
one unit of each other for the novelty suppressed feeding test were recalculated by both 
independent reviewers until they were within said range, then averaged. The standardized 
mean difference (SMD) calculations between both independent reviewers were also 
confirmed to be within 0.05 of each other. 
Quality Assessment 
Potential bias was evaluated using a modified version of SYRCLE’s risk-of-bias 
tool (Hooijmans et al., 2014). SYRCLES’s risk-of-bias tool was adapted to include four 
additional evaluation measures: control for the locomotor effects of CBs, sample size 
calculations, conflict of interest statements, and proper vehicle administration (Macleod 
et al., 2015). Risk-of-bias evaluations were conducted by two independent reviewers 
(N.R. and C.C). Disagreements between reviewers on risk-of-bias evaluations were 




Figure 2. Levels of Dependencies. Five levels of dependencies identified in the meta-
analysis. The main mixed effect model is a multilevel model nesting the effect sizes 
within measurement type studies, study groups, and articles. Furthermore, the effect size 










































DATA ANALYSIS  
 
Statistical Analysis 
The meta-analysis was performed using the metaphor package in R (v4.0.2) 
software (RCoreTeam, 2020; Viechtbauer, 2010). Although all behavioral and 
neuroendocrinological measures were collected, meta-analyses were conducted for the 
most common behavioral measures in the interest of statistical power. A random effects 
model was used to account for the variance due to methanological heterogeneity and a 
multilevel model was used to model dependencies between articles, study groups, and 
measurement type studies (Vesterinen et al., 2014).  
In the present study, five levels of dependencies were identified: laboratories, 
articles, study groups, measurement type studies, and control groups. At the laboratory 
level, research is usually published from a similar group of investigators sharing the same 
equipment. The laboratory level was the only level of dependency that was not able to be 
addressed by the multilevel model since the remaining levels were prioritized as greater 
sources of dependencies. Laboratory level dependency can overlap with article level 
dependency. Examples of laboratory and article level dependencies include shared 
subject pools, protocols, and analysis methods (Tipton, 2015). At the study level, a single 
article can consist of multiple correlated studies sharing similar research designs 
(Vesterinen et al., 2014). At the measurement type level, the same group of subjects can 
be used for multiple tests and multiple different measurements can be collected from the 
same test (Vesterinen et al., 2014). At the control group level, the same measurements 
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from multiple experimental groups are compared to the same control group (Vesterinen et 
al., 2014).  
For continuous measures of stress-coping behaviors (e.g. immobility time in 
seconds in a forced swim test), a SMD for vehicle CUS and CB-treated CUS groups was 
calculated. The SMD, also known as Hedge’s G is similar to Cohen’s D because they 
both utilize a pooled standard deviation (Lakens, 2013). Hedge’s G is usually preferred in 
meta-analyses because this effect size corrects for biases in small sample sizes (Lakens, 
2013; Vesterinen et al., 2014). A restricted maximum likelihood estimate method was 
used in the models to avoid underestimation of the variance or bias in the estimation of 
variance (Vesterinen et al., 2014). Categorical moderators of this meta-analysis were 
species (rats vs. mice), method of administration (systemic vs. site-specific), timing of 
administration relative to CUS (before vs. after vs. both), overall effect on the ECS 
(enhancement vs. inhibition vs. neutral) and co-administration (yes vs. no). Continuous 
moderators were dose of the CB, number of administrations, and days of stress. In one 
article, days of stress were given in a range, so the lowest value was used for a 
conservative estimate (García-Gutiérrez et al., 2010). For the two articles that 
administered CBs every two days, the number of administrations was counted by 
assuming that the first administration began on the first day (Zhang et al., 2015; Zhong et 
al., 2014). There was no missing moderator data. However, it is important to note that 
there were not enough effect sizes to be able to conduct two proposed moderator analyses 
for the effects of model (control vs. disease) and sex (males vs. females) with three effect 
sizes for disease models and four effect sizes for females. 
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Separate subgroup meta-analyses were also conducted for each test measurement 
as an additional method to address measurement type study level dependency. To address 
control group level dependency, if there were multiple different CB-treated CUS groups 
compared to a single vehicle CUS group, the SMD was calculated for each group, and a 
nested weight (based on precision which is regarded as the inverse of variance) was 
created so that every effect size compared to the same control group shared the same 
weight. This nested control group weight allowed for separate SMD measurements while 
addressing dependency between measurements with the same control group.  
Potential publication bias from funnel plot asymmetry was assessed using Egger 
regression (Egger, Smith, Schneider, & Minder, 1997). Between-study and within-study 
heterogeneity was evaluated using the #%	statistic with #% of more than 25%, 50%, and 
75% selected to reflect low, moderate, and high heterogeneity respectively (Higgins, 






Article Selection and Characteristics 
 
 This meta-analysis contains 26 articles from 20 independent laboratory groups. 
From these articles, there are 35 study groups, producing a total of 70 measurement type 
studies for all five test measurements: 1) anhedonia; 2) learned helplessness; 3) novelty 
suppressed feeding; 4) time spent in the anxiogenic context; 5) entries into the anxiogenic 
context. These five meta-analyses are composed of 165 effect sizes (Figure 2). Twelve 
articles used rats as experimental subjects and 14 articles used mice.  
The stress schedule was between ten to 73 days with one to four stressors per day 
for an average of 34 days of stress (Table 1). Subjects received between four to 17 
different types of stressors, with the most common stressors being “food and/or water 
deprivation” and “wet bedding or water” each accounting for 12% of the total types of 
stressors administered (Table 2). Aside from CBs, compounds targeting serotonin 
receptors or reuptake (i.e. WAY100635 and sertraline, respectively) and nicotinic 
acetylcholine receptors (i.e. nicotine) were administered in three articles but were all able 
to be controlled for with a corresponding study matched control group (Buran, Etem, 
Tektemur, & Elyas, 2017; Fogaça et al., 2018; Pekala et al., 2018; Vesterinen et al., 
2014). Additional treatments include repetitive transcranial magnetic simulation (rTMS), 
which was controlled for in one of the two articles (H.-n. Wang et al., 2014). In the other 
article, there was one study where rTMS was administered to both the vehicle CUS and 
CB-treated CUS groups and therefore could not be controlled for (Fang & Wang, 2018). 
The effect sizes from this article were kept in the meta-analysis and addressed in the co-
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treatment moderator analysis as co-treatments (Fang & Wang, 2018). Finally, one article 
conducted an additional treatment of a middle cerebral artery occlusion surgery that could 
not be controlled for because the surgery was performed on all CUS subjects (S. Wang et 
al., 2016). This article was kept in the meta-analysis and this additional intervention was 
addressed by adding a “high” evaluation score to be factored into the bias score for the 
sensitivity analysis (Table 7) (Reis et al., 2019; S. Wang et al., 2016). 
The most common method of administration was intraperitoneal injection, with 
21 out of 26 articles containing studies in which CBs were administered through 
intraperitoneal injections. In three studies, CBs were administered orally (Griebel, 
Stemmelin, & Scatton, 2005; Jin et al., 2015; Xu et al., 2019). In one study the AEA was 
administered subcutaneously, and in another study the CBD was administered 
intravenously (Buran et al., 2017; Xu et al., 2019). In four studies, CBs were 
administered intracranially to the hippocampus (CA1), PFC, BLA, and ventral medial 
hypothalamus (VMH) after CUS (Fang & Wang, 2018; McLaughlin et al., 2013; Segev et 
al., 2014; S. Wang et al., 2016). In addition to these four studies, there were five other 
studies in which CBs were administered after CUS, for a total of nine studies. In 
comparison, the most common administration schedule was during CUS, with 19 articles 
containing studies in which CBs were administered during CUS (and two articles with 
studies in which CB administration continued a few days after CUS).  
CBs were administered between one and 56 times. Fifteen articles administered 
their CB daily. Three articles administered their CB’s twice daily (Ferizovic et al., 2020; 
García-Gutiérrez et al., 2010; Jankovic et al., 2020). Two articles administered JZL184 
every two days (Zhang et al., 2015; Zhong et al., 2014). One article administered CBD 
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weekly (Xu et al., 2019). Only one study used a disease model (i.e. glial fibrillary acidic 
protein thymidine kinase transgenic mice) and two articles from the same laboratory used 





Table 1. Article Characteristics. CUS – Chronic unpredictable stress, GFAP-TK – glial fibrillary acidic protein thymidine kinase 
transgenic mice, AEA- Anandamide, CBD – Cannabidiol, rTMS – repetitive transcranial magnetic simulation,  THC - 
tetrahydrocannabinol, i.p. – intraperitoneal, s.c. – subcutaneous, p.o. – oral, CA1 – first region in the hippocampus, vmPFC – 
ventromedial prefrontal cortex. 
 
 




Treatment(s) Administration Schedule 
Bortolato et al., 2007 200g Male Wistar Rats 70 days 
(2-3/day) 
9 URB597 0.03, 0.1, and 0.3 mg/kg (i.p.) Daily - last 35 days of CUS (35 total) 
Buran, Etem, Tektemur, & 
Elyas, 2017 




11 AEA 5 mg/kg (s.c.) and Sertraline 10 mg/kg (i.p.) After CUS (3 total) 
Campos et al., 2013 Male GFAP-TK and C57BL/6J 
Mice (90 days old) 
14 days 
(1/day) 
6 CBD 30 mg/kg (i.p.) and AM251 1 mg/kg (i.p.) Daily - Concurrent with CUS (14 total) 




8 rTMS and AM251 1 mg/kg (i.p.) or 0.35 ng/0.5𝜇l/side 
(intra-CA1) 
Daily - 7 days after CUS (7 total) 
Ferizovic, Spasojevic, 
Stefanovic, Jankovic, & 
Dronjak, 2020 
250-300g Male and Female Wistar 
Rats (77 days old) 
42 days 
(2/day) 
13 URB597 0.3 mg/kg (i.p.) Twice daily - last 14 days of CUS (28 
total) 
Fogaça, Campos, Coelho, 
Duman, & Guimarães, 
2018 
20-26g Male C57BL/6J Mice (56-
63 days old) 
14 days 
(1/day) 
8 CBD 30 mg/kg (i.p.), AM251 0.3 mg/kg (i.p.), AM630 
0.3 mg/kg (i.p.), and WAY100635 0.05 mg/kg (i.p.) 
Daily - Concurrent with CUS (14 total) 




7 THC 0.5 and 1 mg/kg (i.p.) After CUS (1 total) 
Gall et al., 2020 355-419g Adult Male Wistar Rats 28 
(2/day) 
11 CBD 10 mg/kg (i.p.) Daily - Concurrent with CUS and 4 days 
after (32 total) 
García-Gutiérrez, Pérez-
Ortiz, Gutiérrez-Adán, & 
Manzanares, 2010 
25-35g Male Swiss ICR Mice (60-




7 AM630 1 mg/kg (i.p.) Twice daily - last 28 days of CUS (56 
total) 
Griebel, Stemmelin, & 
Scatton, 2005 
20-27g Male BALB/c Mice 49 days 
(1-3/day) 
4 Rimonabant 10 mg/kg (p.o.) Daily - last 35 days of CUS (35 total) 




6 HU-210 10 and 50 𝜇g/kg (i.p.) After CUS (1 total) 
Hwang et al., 2020 167-183g Male Sprague Dawley 
Rats (49 days old) 
28 days 
(1-2/day) 
4 𝛽-Caryophyllene 25, 50, and 100 mg/kg (i.p.) Daily - Concurrent with CUS (28 total) 
Ishiguro et al., 2018 20-25g Male  C57BL/6J Mice (56-
70 days old) 
14 
(2/day) 
6 AM630 3 mg/kg (i.p.) and JWH015 20 mg/kg (i.p.) Daily - Concurrent with CUS (14 total) 
Jankovic, Spasojevic, 
Ferizovic, Stefanovic, & 
Dronjak, 2020 
250-300g Male and Female Wistar 
Rats (77 days old) 
42 days 
(2/day) 
13 URB597 0.3 mg/kg (i.p.) Twice daily - last 14 days of CUS (28 
total) 
Jin, Yu, Tian, Zhang, & 
Quan, 2015 
18-22g Adult Male Kunming Mice  28 days 
(2/day) 
14 Oleoylethanolamide 1.5, 3, 6 mg/kg (p.o.) Daily - last 21 days of stress (21 total) 
Lomazzo et al., 2015 Male C57BL/6J Mice (42 days old) 73 days 
(2-3/day) 
17 URB597 1 mg/kg (i.p.) and JZL184 8 mg/kg (i.p.) Daily - last 38 days of stress (38 total) 
Lomazzo, Köing, Abassi, 
Jelinek, & Lutz, 2017 
Male C57BL/6J Mice (42 days old) 73 days 
(2-3/day) 
17 URB597 1 mg/kg (i.p.) Daily - last 38 days of stress (38 total) 
McLaughlin et al., 2013 300g Male  Sprague Dawley Rats 
(70 days old) 
21 days 
(2-3/day) 
8 AM251 0.28 ng/0.2𝜇l/side (intra-vmPFC) After CUS (1 total) 
Onaivi et al., 2008 Male and Female BALB/c Mice 28 days 6 JWH015 20 mg/kg (i.p.) and AM630 1 and 3 mg/kg (i.p.) Daily - Concurrent with CUS (28 total) 
Pekala, Michalak, Kruk-
Slomka, Budzynska, & 
Biala, 2018 




7 Nicotine 0.1 and 0.2 mg/kg (s.c.),  Oleoylethanolamide 
2.5 mg/kg (i.p.), AM251 0.25 mg/kg (i.p.), JWH133 2 
mg/kg (i.p.), and AM630 2 mg/kg (i.p.) 




Table 1. Article Characteristics (continued). CUS – Chronic unpredictable stress, rTMS – repetitive transcranial magnetic simulation, 
CBD – Cannabidiol, ACEA - Arachidonyl-2-chloroethylamide, i.p. – intraperitoneal, p.o. – oral, i.v. – intravenous, BLA – basolateral 
amygdala, VMH – ventral medial hypothalamus.  
 
Table 2. Stress Types. Proportion of stress types used across articles.
 




Treatment(s) Administration Schedule 
Segev, Rubin, Abush, 
Richter-Levin, & Akirav, 
2014 




8 WIN55,212-2 0.5 mg/kg (i.p.) and 5𝜇g/0.5𝜇l/side (intra-
BLA) 
Daily - last 3 days of CUS (i.p. 3 total); 
After CUS (intra-BLA 1 total) 




14 rTMS and AM251 1 mg/kg (i.p.) Daily - 7 days after CUS (7 total) 
Wang et al., 2016 250-270g Male Sprague Dawley 
Adult Rats 
18 days 9 Middle cerebral artery occlusion surgery, ACEA 1 and 10 
(i.p.) or 0.2 and 2 𝜇g/0.5𝜇l/side (intra-VMH), JWH133 1 
and 5 mg/kg (i.p.) or 0.3 and 3 𝜇g/0.5𝜇l/side (intra-VMH) 
Daily - first 7 days of CUS (i.p. 7 total) ; 
After CUS (intra-VMH 1 total) 
Xu et al., 2015 32-38g Male ICR Mice (42 days 
old) 
35 days 4 CBD 10 (i.v.), 10, and 100 (p.o.) Weekly - last 28 days of CUS (4 total) 




11 JZL184 8 mg/kg (i.p.) Every two days - last 14 days of stress and 
7 days after (11 total) 
Zhong et al., 2014 17-25g Male C57BL/6J Mice (56-
70 days old) 
35 days 
(2/day)  
11 JZL184 8 mg/kg (i.p.) and Rimonabant 2 mg/kg (i.p.) Every two days - 21 days of CUS and 7 
days later (14 total); Every two days - last 
day of CUS and 7 days later (4 total) 
 
 
Stressor %  
Light and Circadian Rhythm  
Stroboscopic Light Flashes 





Tilted Cage  
Repeated Cage Changing 
Removal of Bedding  














Temperature (Hot or Cold) 
Foreign Object or Odor 






Restraint or Immobilization 8 
Food and/or Water Deprivation 12 
Forced Swimming Test 5 
Pain (Tail Suspension Test, Tail Pinch, or Foot Shock) 3 
 




Cannabinoid-Related Effects  
All CB-related measurements between the vehicle CUS and CB-treated CUS 
groups were included in Table 3. CBD at a dose of 30 mg/kg inhibits and significantly 
reduces FAAH expression in the hippocampus, while URB597 at dose of 0.3 mg/kg 
inhibits and significantly reduces FAAH expression in the striatum, midbrain, and 
hippocampus (Bortolato et al., 2007; Fogaça et al., 2018). Complimentary to these 
effects, URB597 at dose of 1 mg/kg significantly increases AEA and PEA levels in the 
cingulate, PFC, hypothalamus, and midbrain (Lomazzo et al., 2015). In the midbrain, 
URB597 at dose of 0.3 mg/kg significantly increases levels of OEA (in addition to AEA 
and PEA) and decreases CB1R expression (Bortolato et al., 2007; Lomazzo et al., 2015). 
Finally, AM630 at a dose of 1 mg/kg and BCP at a dose of 25 and 50 mg/kg (but not 100 
mg/kg) increase CB2R genetic and protein expression, respectively, compared to their 
vehicle CUS groups (García-Gutiérrez et al., 2010; Hwang et al., 2020).  
Stress-Related Effects  
Only the most common measurements between the vehicle CUS vehicle and CB-
treated CUS groups were included in the interest of creating a cohesive overview (Table 
4). A complete table is available on the Open Science Framework (https://osf.io/csgmf/). 
It is important to also mention two articles which measured hormone levels. In one 
article, rat hair CORT was measured before and after CUS (Gáll et al., 2020). In the 
vehicle group, CUS significantly reduced CORT levels, and in the CBD group, CUS 
slightly increased CORT levels (Gáll et al., 2020). Gáll and colleagues hypothesize that 
this decrease in CORT levels in the vehicle CUS group reflects HPA axis hypofunction 
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that was prevented by CBD treatment (Gáll et al., 2020). In the other article, OEA 
administered at a dose of 6 mg/kg (but not 1.5 or 3 mg/kg) during CUS significantly 
reduced serum ACTH and CORT levels compared to the vehicle CUS group (Jin et al., 
2015). Furthermore, OEA administered at a dose of 6 mg/kg (but not 1.5 or 3 mg/kg) 
during CUS significantly reduced the adrenal index (measured as the bilateral adrenals 
weights / body weight) compared to the vehicle CUS group (Jin et al., 2015). Both 
articles measuring hormone levels support the notion that CB administration prevents 
HPA axis dysregulation, demonstrated by hormone levels that are more comparable to 




Table 3. Cannabinoid-Related Effects. ↓ and ↑ represent a statistically significant decrease or increase (respectively) while ↔ 
represents a non-significant or unclear change. Drug doses are administered intraperitoneally and consistent within the article unless 
stated otherwise. LC-MRM – liquid chromatography multiple reaction monitoring, qRT-PCR - quantitative real time polymerase 
chain reaction, ChIP – chromatin immunoprecipitation, double in situ – double in situ hybridization, LC-MS – liquid chromatography 
mass spectrometry, FAAH – fatty acid amide hydrolase, CBD – Cannabidiol, AEA – anandamide, PEA – palmitoyl-ethanolamide, 
OEA – oleoyl-ethanolamide, 2-AG – 2-arachydonylglycerol, MAGL – monoacylglycerol lipase, CB1/CB1R – cannabinoid 1 receptor, 
CB2R – cannabinoid 2 receptor H3K9ac – histone 3 lysine 9 acetylation H4K8ac – histone 4 lysine 8 acetylation, GAD65 – glutamic 
acid decarboxylase 65 kilodalton.  
 
Brain Region Measure Treatment Expression  Subjects Author, year 
Cingulate 
 
LC-MRM URB597 1 mg/kg and URB597 + JZL184 
JZL184 8 mg/kg  
JZL184 8 mg/kg and URB597 + JZL184 
URB597 1 mg/kg 
↑ AEA and PEA  
↔ AEA and PEA 
↑ 2-AG 
↔ 2-AG 
Male C57BL/6J Mice (42 
days old) 
Lomazzo et al., 2015 
Cingulate qRT-PCR 
ChIP 
Double in situ  
URB597 1 mg/kg ↔ CB1R, FAAH, and MAGL 
↔ CB1-H3K9ac and CB1-H4K8ac 
↔ CB1 on 𝐺𝐴𝐷65+ and 𝐺𝐴𝐷65−neurons 
Male C57BL/6J Mice (42 
days old) 




LC-MRM URB597 1 mg/kg and URB597 + JZL184 
JZL184 8 mg/kg 
JZL184 8 mg/kg and URB597 + JZL184 
URB597 1 mg/kg 
↑AEA and PEA 
↔ AEA and PEA 
↑ 2-AG 
↔ 2-AG 
Male C57BL/6J Mice (42 
days old) 
Lomazzo et al., 2015 
PFC LC-MS 
qRT-PCR 
URB597 0.1, 0.03, and 0.3 mg/kg 
URB597 0.3 mg/kg 
↔ AEA 
↓ CB1R 
200g Male Wistar Rats Bortolato et al., 2007 
Thalamus LC-MS URB597 0.3; 0.1 and 0.03 mg/kg ↑ AEA; ↔ AEA 200g Male Wistar Rats Bortolato et al., 2007 
Hypothalamus 
 
LC-MRM URB597 1 mg/kg and URB597 + JZL184  
JZL184 8 mg/kg 
JZL184 8 mg/kg and URB597 + JZL184 
URB597 1 mg/kg 
↑ AEA and PEA 
↔ AEA and PEA 
↑ 2-AG 
↔ 2-AG 
Male C57BL/6J Mice (42 
days old) 





URB597 0.3; 0.1 and 0.03 mg/kg 
URB597 0.3 mg/kg 
↑ AEA; ↔ AEA 
↓ FAAH 





URB597 0.3; 0.1 and 0.03 mg/kg 
URB597 0.3 mg/kg 
 
URB597 0.3 and 0.1 mg/kg 
URB597 0.03 mg/kg 
↑ AEA; ↔ AEA 
↓ FAAH 
↓ CB1R  
↑ OEA and PEA 
↔ OEA and PEA 
200g Male Wistar Rats Bortolato et al., 2007 
Midbrain 
 
LC-MRM URB597 1 mg/kg and URB597 + JZL184 
JZL184 8 mg/kg 
JZL184 8 mg/kg and URB597 + JZL184 
URB597 1 mg/kg 
↑AEA and PEA 
↔ AEA and PEA 
↑ 2-AG 
↔ 2-AG 
Male C57BL/6J Mice (42 
days old) 




URB597 0.1, 0.03, and 0.3 mg/kg 
URB597 0.3 mg/kg 




200g Male Wistar Rats Bortolato et al., 2007 
Hippocampus  Western Blot CBD 30 mg/kg ↓ FAAH 20-26g Male C57BL/6J 
Mice (56-63 days old) 






LC-MRM URB597 1 mg/kg and URB597 + JZL184 
JZL184 8 mg/kg 
JZL184 8 mg/kg and URB597 + JZL184 
URB597 1 mg/kg 
↔ AEA and ↑PEA 
↔ AEA and PEA 
↑ 2-AG 
↔ 2-AG 
Male C57BL/6J Mice (42 
days old) 
Lomazzo et al., 2015 
Hippocampus qRT-PCR AM630 1 mg/kg ↑ CB2R  25-35g Male Swiss ICR 
Mice (60-90 days old) 
García-Gutiérrez, Pérez-Ortiz, 
Gutiérrez-Adán, & Manzanares, 2010 




167-183g Male Sprague 
Dawley Rats (49 days old) 




Table 4. Stress-Related Effects. ↓ and ↑ represent a statistically significant decrease or increase (respectively) while ↔ represents a 
non-significant or unclear change. Drug doses are administered intraperitoneally and consistent within the article unless stated 
otherwise. p.o. – oral, i.v. – intravenous, ELISA – enzyme-linked immunosorbent assay, qRT-PCR - quantitative real time polymerase 
chain reaction, IHC – immunohistochemistry, Electrophys – electrophysiology, rTMS – repetitive transcranial magnetic simulation, 
CBD – Cannabidiol, BDNF – brain derived neurotropic factor, BrdU – bromodeoxyuridine, DCX – doublecortin, NeuN – neuronal 
nuclear protein, fEPSP – field excitatory post synaptic potential, LTP – long term potentiation.
 
Brain Region Measure Treatment Expression  Subjects Author, year 
mPFC 
 
ELISA Oleoyl-ethanolamide 1.5, 3 and 6 mg/kg  p.o. ↑ BDNF 18-22g Adult Male 
Kunming Mice 





CBD 100 mg/kg p.o. and 10 mg/kg i.v. 
CBD 10 mg/kg p.o. 
↑ BDNF 
↔ BDNF 
32-38 g Male ICR Mice 
(42 days old) 
Xu et al., 2015 
Hippocampus 
 
ELISA Oleoyl-ethanolamide 1.5, 3 and 6 mg/kg  p.o. ↑ BDNF 18-22g Adult Male 
Kunming Mice 





CBD 10 mg/kg p.o., 100 mg/kg p.o., and 10 mg/kg i.v. ↔ BDNF 32-38 g Male ICR Mice 
(42 days old) 
Xu et al., 2015 
Hippocampus Western Blot 𝛽-caryophyllene 25, 50 and 100 mg/kg  
 
↑BDNF 167-183g Male Sprague 
Dawley Rats (49 days 
old) 
Hwang et al., 2020 
Hippocampus qRT-PCR 
IHC 
AM630 1 mg/kg ↔BDNF (increased trend) 
↔BDNF  
25-35 g Male Swiss ICR 
Mice (60-90 days old) 
García-Gutiérrez, Pérez-Ortiz, 







rTMS + AM251 1 mg/kg 
AM251 1 mg/kg 
rTMS + AM251 1 mg/kg 
AM251 1 mg/kg 
↓ BDNF   
↔ BDNF  
↓ 𝐵𝑟𝑑𝑈+cells 
↔ 𝐵𝑟𝑑𝑈+cells  
180-230 g Male Sprague 
Dawley Adult Rats 
Wang et al., 2014 
Hippocampus  
(subgranular zone) 
IHC CBD 30 mg/kg ↑ 𝐵𝑟𝑑𝑈+cells 
↑ 𝐷𝐶𝑋+cells 
Male C57BL/6J Mice 
(90 days old) 
















AM251 0.3 mg/kg  and/or CBD 30 mg/kg  
AM630 0.3 mg/kg and AM630 + CBD 
CBD 30 mg/kg , AM251 0.3 mg/kg and AM630 + CBD 
CBD + AM251 and AM630 0.3 mg/kg 
AM630 + CBD, AM251 0.3 mg/kg and/or CBD 30 mg/kg 
AM630 0.3 mg/kg 
AM251, AM630, AM251 + CBD and AM630 + CBD 






↑ 𝐷𝐶𝑋+ cells 
↔ 𝐷𝐶𝑋+ cells 
↑ 𝐵𝑟𝑑𝑈+cells 
↔ 𝐵𝑟𝑑𝑈+cells 
↑ 𝑁𝑒𝑢𝑁 + 𝐵𝑟𝑑𝑈+ 
↔ 𝑁𝑒𝑢𝑁 + 𝐵𝑟𝑑𝑈+ 
↔ 𝐷𝐶𝑋+cell migration 
↑ 𝐷𝐶𝑋+cell migration 
↑ Secondary and tertiary spines 
↑ Total dendritic length 
↑ Total number of branches 
↑ Number of spines 
↔  Number of spines 
20-26g Male C57BL/6J 
Mice (56-63 days old) 








JZL184 8 mg/kg 
 
JZL184 8 mg/kg 
 
 
JZL184 8 mg/kg + picrotoxin 
 
↑ 𝐷𝐶𝑋+ cells 
↑ 𝐵𝑟𝑑𝑈+cells 
↔ pair-pulse ratio 
↑ fEPSP slope and slope % 
↑ LTP magnitude % 
↔ fEPSP slope % 
↔  LTP magnitude 
Male C57BL/6J Mice 
(56-70 days old) 





Electrophys Day 23: WIN55,212-2 0.5 mg/kg 
WIN55,212-2 0.5 mg/kg + AM251 0.3 mg/kg 
RU-38486 10 mg/kg and WIN55,212-2 + RU-38486 
Day 28: WIN55,212-2 
↑ LTP amplitude and slope 
↔ LTP amplitude and slope 
↑ LTP amplitude and slope 
↔ LTP amplitude and slope 
Male Sprague Dawley 
Rats (45 days old) 
Segev, Rubin, Abush, Richter-Levin, 
& Akirav, 2014 
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Cannabinoid Efficacy 
 The excel files containing the full datasets with moderators and the R markdown 
code file containing all statistical analyses are both available on the Open Science 
Framework (https://osf.io/csgmf/). The main mixed effects model nesting the effect sizes 
within measurement type studies, study groups, and articles with effect size weights 
nested within control groups revealed a significant pooled SMD of 0.4456 (95% CI 
0.0498 – 0.8415, p = 0.0274), indicating that CB administration rescues the overall 
negative effects of CUS on anhedonia, learned helplessness, novelty suppressed 
feeding, and exploration anxiety in comparison to placebo. Separate meta-analyses 
nesting the effect sizes within study groups and articles with effect size weights nested 
within control groups were conducted for each of the five test measurements. Entries into 
the anxiogenic context revealed a SMD of 0.6231 (95% CI -0.0095 – 1.2558, p = 0.0535) 
an effect that was likely unable to reach significance because it has less statistical power 
than the main model. These separate analyses suggest that future studies should continue 
to investigate the effect of CBs on entries into the anxiogenic context in CUS. In the 
separate meta-analysis for learned helplessness (i.e. immobility time), an exploratory 
moderator analysis on the effect of the studies’ test time revealed that test time did not 
significantly affect the SMD ! =  0.2244 (95% CI -0.0376 – 0.4865, p = 0.0932) 
indicating that the immobility time measurement was not affected by the test time. This 
result should be interpreted with caution because this model has less statistical power 
than the main model.    
Moderator analyses were conducted on a mixed effects model nesting the effect 
sizes within study groups and articles with effect size weights nested within control 
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groups. Measurement type studies was included in the model as the second moderator for 
all moderator analyses. The effect of co-treatments was originally proposed to be 
addressed by adjusting the studies’ weight, but without a quantifiable measurement to 
adjust the weight of co-treatment studies, this effect was instead addressed with a 
moderator analysis. A moderator analysis on the model revealed that for CB treatments 
that did not include an additional treatment (i.e. not a co-treatment) there was a 
significant SMD of 0.7919 (95% CI 0.1387 – 1.445, p = 0.0175). This co-treatment 
moderator analysis is likely a better representation of the efficacy of CBs on stress-
coping behaviors in CUS since a sizeable amount of co-treatment effect sizes combined 
CB agonists with CB antagonists. In support of this interpretation, a moderator analysis 
on the model revealed that for CBs that enhance the ECS there was a significant SMD of 
0.7809 (95% CI 0.1281 – 1.4337, p = 0.019). These data support the continuation of 
research on the effect of CBs which enhance the ECS on stress-coping behaviors in CUS.  
The model was not significantly moderated by the method of administration. For 
CBs administered systemically there was SMD of 0.6231 (95% CI -0.0453 – 1.2916, p = 
0.0677) and for CBs administered in a site-specific manner there was a SMD of -0.028 
(95% CI -1.1401 – 1.0841, p = 0.9607). The method of administration moderator analysis 
should be interpreted with caution as there were only nine effect sizes with site-specific 
intracranial administration. A moderator analysis on the model revealed that for CB 
administration during CUS there was a significant SMD of 0.8043 (95% CI 0.3022 – 
1.3065, p = 0.0017). These data suggest that CBs are more efficacious at regulating the 
HPA axis during CUS rather than after CUS. For the timing of CB administration relative 
to CUS, the “after” and “both” moderators should be interpreted with caution. The “both” 
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moderator should be interpreted with caution due to statistical power, with 97 effect sizes 
for the “during” moderator, 49 effect sizes for the “after” moderator, and only 19 effect 
sizes for the “both” moderator. The “after” moderator should be interpreted with caution 
because a proportion of the effect sizes administering CBs after CUS also administered 
CBs once intracranially.  
The model was significantly moderated by the number of CB administrations, 
meaning that every additional administration increased the SMD by a value of ! = 0.0262 
(95% CI 0.0026 – 0.0499, p = 0.0295). Hillard and colleagues hypothesize that the effects 
of CBs on the HPA axis depends on the eCB tone (i.e. the amount of eCBs in an 
individual’s ECS) with a high eCB tone facilitating effective HPA axis termination 
(Hillard et al., 2018). Therefore, it is possible that chronic CB treatment artificially 
maintains a high eCB tone. The model was also significantly moderated by the dose, 
meaning that every additional mg/kg increased the SMD by a value of	! =  0.0209 (95% 
CI 0.0078 – 0.0339, p = 0.0018). It is important to take into consideration that the dose 
moderator was conducted on a dataset which removed site specific and co-treatment 
effect sizes. The effect of dose possibly reflects the development of tolerance to CBs and 
the need to maintain this high eCB tone, thereby supporting the need to continue 
investigating CB-based drugs that do not directly target the CB receptors.  
A moderator analysis on the model revealed that for mice there was a significant 
SMD of 0.7772 (95% CI 0.0512 – 1.5032, p = 0.0359). Although the differences between 
rats and mice exposed to CUS has not been formally investigated, it appears that at least 
anecdotally, mice have higher stress reactivity than rats (Kent Scientific Corporation, 
2019). If this observation is true, then it is possible that CBs exhibit greater efficacy on 
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mice because mice exhibit a greater reaction to CUS. Regardless, further investigation is 
needed on the differences between species on the effects of CBs on stress-coping 
behaviors in CUS. 
Surprisingly the model was not significantly moderated by the number of days of 
stress ! =  0.0096 (95% CI -0.0122 – 0.0315, p = 0.3878). These data suggest that the 
efficacy of CBs on stress-coping behaviors is not significantly affected by the severity of 
the CUS paradigm. Therefore, future studies should focus less on the severity of the CUS 
paradigm and focus more on conducting CUS with female rodents or disease models (e.g. 
for depression and anxiety) to investigate the efficacy of CBs on stress-coping behaviors 
in CUS. The lack of effect sizes needed to conduct the proposed moderator analyses on 
the effects of model (control vs. disease) and sex (males vs. females) further emphasizes 
the need to investigate this gap in the literature. 
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Figure 3. Anhedonia. Meta-analysis of studies investigating the effect of CB 
administration in CUS on anhedonia (i.e. sucrose intake or preference). All measures are 
of % sucrose preference unless stated otherwise. BW – body weight, SMD – 
Standardized mean difference, CI – confidence interval, rTMS – repetitive transcranial 
magnetic simulation, CBD – Cannabidiol, OEA – oleoyl-ethanolamide, VMH – ventral 
medial hypothalamus, CA1 – first region in the hippocampus, RIM – rimonabant, ACEA 
- Arachidonyl-2-chloroethylamide. 
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Figure 4. Learned Helplessness. Meta-analysis of studies investigating the effect of CB 
administration in CUS on learned helplessness (i.e. immobility time in seconds for the 
forced swim test or tail suspension test). Sec – total time of the test in seconds used for 
analysis, FST – forced swim test, TST – tail suspension test, SMD – Standardized mean 
difference, CI – confidence interval, AEA – anandamide, rTMS – repetitive transcranial 
magnetic simulation, RIM – rimonabant, BCP - !-Caryophyllene, vmPFC – ventromedial 
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Figure 5. Novelty Suppressed Feeding. Meta-analysis of studies investigating the effect 
of CB administration in CUS on anxiety in the novelty suppressed feeding test (i.e. 
latency to consume food in a novel environment). SMD – Standardized mean difference, 
CI – confidence interval, CBD – Cannabidiol, GFAP-TK – glial fibrillary acidic protein 
thymidine kinase transgenic mice, rTMS – repetitive transcranial magnetic simulation, 
CA1 – first region in the hippocampus, RIM – rimonabant. 
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Figure 6. Time in the Anxiogenic Context. Meta-analysis of studies investigating the 
effect of CB administration in CUS on exploration anxiety (i.e. % or total time spent in 
the anxiogenic context). Sec – total time of the test in seconds, EPM – elevated plus 
maze, OFT – open field test, EZM – elevated zero maze, LDB – light dark box test, SMD 
– Standardized mean difference, CI – confidence interval, CBD – Cannabidiol, GFAP-
TK – glial fibrillary acidic protein thymidine kinase transgenic mice, THC – 
tetrahydrocannabinol, RIM – rimonabant. 
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Figure 7. Entries into the Anxiogenic Context. Meta-analysis of studies investigating the 
effect of CB administration in CUS on exploration anxiety (i.e. % or # of entries into the 
anxiogenic context). EPM – elevated plus maze, OFT – open field test, LDB – light dark 
box test SMD – Standardized mean difference, CI – confidence interval, CBD – 
Cannabidiol, GFAP-TK – glial fibrillary acidic protein thymidine kinase transgenic mice, 






 43  
 
Bias Assessment 
 The risk of bias across articles can be viewed in Figure 8. Overall, preclinical 
research can greatly benefit from reporting the measures taken to reduce the risk of bias 
(Macleod et al., 2015). When evaluating baseline characteristics, all articles reported sex 
and usually either the weight or age of the subjects. In neuroscience research, both 
characteristics are important when considering measures such as the effect of a treatment 
or the effect on the subject’s brain, respectively. When conducting research with rodents, 
it is not always possible to control for litter effects initially due to housing constraints. 
Unfortunately, not a single article statistically controlled for the variance shared by 
littermates, which has the potential of increasing the likelihood of committing an error 
(Sequeira-Cordero, Salas-Bastos, Fornaguera, & Brenes, 2019). Controlling for baseline 
characteristics is especially important in collaborative research, which resulted in the two 
“high” scores.  
When evaluating allocation concealment, most articles were “unclear” about how 
the CUS schedule was generated. Two articles explicitly stated that the same weekly 
schedule was repeated which can negatively impact the efficacy of the CUS paradigm 
since the subjects are more likely to habituate to a weekly schedule in comparison to a 
completely randomized schedule (Franklin et al., 2012).  
When evaluating random housing, several articles received “high” scores by 
stating that the experimental group was housed in a different room than the control group. 
Housing different groups in different rooms can result in disproportionate exposure to 
noise and differences in colony maintenance by animal technicians, thereby influencing 
stress-coping behaviors. Environmental conditions such illumination and temperature can 
 44  
 
differ between cages on the top and bottom shelf (Hooijmans et al., 2014). Since 
differences in illumination and temperature can also influence stress-coping behaviors, 
environmental conditions need to be properly controlled for by randomly shuffling shelf 
locations between groups (Haller et al., 2007; Hooijmans et al., 2014). In other instances, 
the housing conditions were different between the control and experimental groups (i.e. 
individually or group housed). With social stressors such as isolation and overcrowding, 
it is important that the housing conditions are comparable between control and 
experimental groups since the housing conditions can also influence stress-coping 
behaviors (Sequeira-Cordero et al., 2019).  
When evaluating incomplete outcome data, although two articles received “high” 
scores, five of the more recent articles received “low” scores for reporting the initial size 
of their groups, the group sizes for analysis, and communicating sources of attrition or 
exclusions in their article. In alignment with encouraging this trend towards explicit 
communication of group sizes, sample size calculations should also be communicated. 
Low statistical power, which is commonly observed in preclinical neuroscience research, 
has tremendous consequences in the reliability and reproducibility of results due to 
overestimated effect sizes (Button et al., 2013).  
When evaluating selective outcome reporting, although three articles received 
“high” scores, it is important to recognize the eight articles with “low” scores that 
explicitly stated when data was not shown in their article. However, with unlimited space 
to provide complete datasets with non-significant results in online supplementary 
material or to publish these results publicly using resources such as the Open Science 
Framework, it is sobering that only six out of the 26 articles provided supplementary 
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material. When additional information was directly requested through email, it is 
demoralizing to report that only one researcher was able to provide their dataset. Two 
researchers responded saying they no longer had the original dataset, and another 
researcher was unable to find their original data. In order to avoid the need to directly 
contact researchers for additional information, providing all data in non-graphical form 
and all analysis calculations has immense potential to facilitate the reproducibility of 
work and improve the quality of meta-analytic work in efforts to reduce unnecessary 
animal use (Hooijmans et al., 2010).  
Generally, there was more reporting on conflicts of interest, blinding, and 
randomization of groups (i.e. sequence generation). These trends of increased reporting in 
preclinical neuroscience research are in line with other types of preclinical research 
which should provide hope that there is potential to facilitate continued improvement in 
reporting measures taken to reduce the risk of bias (Macleod et al., 2015). It is also 
interesting to note that despite a subset of articles monitoring body weight and sucrose 
preference throughout stress for validation of the CUS paradigm, only one article 
investigated the locomotor effects of the drugs administered (Onaivi et al., 2008). When 
investigating exploration anxiety, it would be impactful to screen for the locomotor 
effects of the drugs administered or provide a baseline within-subject measure of 
locomotion to control for locomotor effects of the drug. A within-subject baseline 
locomotion measurements in exploration anxiety tests should be considered as standard. 
Similarly to how the latency to consume food in the home cage was measured after all of 
the novelty suppressed feeding tests. This within-subject measure that was taken in 
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addition to the latency to consume food in a novel environment to control for possible 
anxiogenic or orexigenic effects of drugs.  
In line with controlling for the effects of a drug, it is also important to control for 
the stress-inducing effects of injections and any effects of the solvent that is administered 
to the experimental group by administering the same exact solution without the drug (i.e. 
a vehicle) to the control group. Therefore, vehicle administration was added as an 
evaluation criterion. Although the majority of articles reported this form of control in 
their research design, it was surprising to discover that four articles received an “unclear” 
score for not explicitly stating the implementation of such a crucial control in 
pharmacology research.  
A separate sensitivity analysis was conducted by generating a bias score (Table 
7). This bias score was calculated for each article by adding one point for every “low” 
evaluation score and subtracting one point for every “high” evaluation score, then adding 
two points to all of the articles so that the lowest bias score was zero. Two articles were 
removed for having the lowest bias scores, revealing a significant SMD of 0.4547 (95% 
CI 0.0388 – 0.8705, p = 0.0321) which is not substantially different than the pooled SMD 
of 0.4456 (95% CI 0.0498 – 0.8415, p = 0.0274).   
As clearly observed in Figure 8, the most common evaluation score across all 
measures (aside from the conflict of interest and vehicle measures) is “unclear” which 
suggests an overestimation of the treatment effects and a need for more explicit reporting 
of measures taken to reduce the risk of bias (Reis et al., 2019).  
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Figure 8. Risk of Bias Across Articles. Evaluation of included articles. 
Publication Bias and Heterogeneity 
 The main mixed effects meta-analysis model is a multi-level model (i.e. effect 
sizes nested within measurement type studies, study groups, and articles) and utilizes 
effect size weights nested within control groups to address multiple levels of 
dependencies. Currently, there is no single method to evaluate publication bias while 
addressing sample dependency (Rodgers & Pustejovsky, 2020). Ignoring dependency and 
assuming that this meta-analysis is a univariate model rather than a multi-level mixed 
effects model can inflate the type I error rate (Rodgers & Pustejovsky, 2020). Therefore, 
two analyses for publication bias were conducted. The first analysis conducts an Eggar 
regression on the funnel plot with the nested weights. The second analysis conducts an 
Eggar regression on the funnel plot with the nested weights but is only for a subset of the 
effect sizes by selecting the single largest effect size for each of the 26 included articles 
(assuming that articles are published based on their largest effect size). An Egger 
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regression on the funnel plot of the full dataset (Figure 9) revealed the significant 
presence of asymmetry (t = -5.005, df = 163, p < 0.001). Whereas an Egger regression on 
the funnel plot of the subset data (Figure 10) approached the significant presence of 
asymmetry (t = -2.053, df = 24, p = 0.0511). Conflicting findings from these two methods 
of analysis have been previously reported (Rodgers & Pustejovsky, 2020). Since the 
Egger regression on the funnel plot of the subset data approached the significant presence 
of asymmetry, these Eggar regressions suggest that publication bias is present in the 
dataset (Reis et al., 2019). Asymmetrical funnel plots are due to a lack of non-significant 
and opposing findings published (Reis et al., 2019).  
In a multi-level mixed effects model nesting the effect sizes within study groups 
and articles but not within measurement type studies, there was a moderate amount of 
heterogeneity across studies (#!= 69.5218%), indicating inconsistent results (Melsen et 
al., 2014). As expected based on methodological heterogeneity, there was more 
heterogeneity between studies (#!= 46.4898%) than within studies (#!= 23.0319%). 
Separate analyses by test measurement identified anhedonia as the most heterogenous 
measurement (#!= 91.2125%) with a much greater proportion of heterogeneity between 
studies (#!= 86.1742%) than within studies (#!= 5.038%). Entries in the anxiety context 
was the least heterogenous measurement (#!= 64.5820%) with more heterogeneity 
between studies (#!= 51.2359%) than within studies (#!= 13.3462%).  
High heterogeneity and funnel plot asymmetry negatively affect meta-analyses as 
they weaken the external validity of the meta-analysis findings (Reis et al., 2019). The 
most effective moderator in reducing heterogeneity was the time the drug was 
administered relative to CUS (#!= 56.6541%). None of the heterogeneity was between 
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studies (#!= 0%) and all of the heterogeneity was within studies (#!= 56.6541%) 
indicating that all the variances of effect sizes by this moderator was due to sampling 
error or chance (Vesterinen et al., 2014). Although it is tempting to speculate that this 
within study heterogeneity might be due to differences from significant moderators that 
were not identified in this meta-analysis, these data suggest a need to implement multiple 
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Figure 9. Complete Funnel Plot. Funnel plot of all 165 effect sizes using nested weights. 
 
Figure 10. Article Specific Funnel Plot. Funnel plot of the largest effect size for each of 













Implications and Future Directions 
Article Characteristics  
This meta-analysis contains 26 articles and 35 study groups for a total of 165 
effect sizes (Figure 1). Out of the 26 articles, 21 articles contained studies in which CBs 
were administered through intraperitoneal injections, 19 articles contained studies in 
which CBs were administered during CUS, and 15 articles contained studies in which 
CBs were administered daily.  
Cannabinoid-Related Effects 
Some interesting CB-related effects that need to be highlighted are in regard to 
CB1R expression and eCB content in the hippocampus (Table 3). Chronic stress 
downregulates CB1R in the hippocampus, hypothalamus, striatum, and dorsal root 
ganglion (Morena et al., 2016). These findings can partially explain why CBs reduced or 
did not have an effect on CB1R expression in the cingulate, hippocampus, and midbrain 
(Bortolato et al., 2007; Lomazzo et al., 2015). Chronic stress upregulates CB1R in the 
PFC, and in this same study the vehicle CUS group demonstrated significantly increased 
CB1R expression compared to the vehicle non-stressed group (Bortolato et al., 2007). 
Therefore, URB597 at a dose of 0.3 mg/kg was likely able to inhibit enough FAAH to 
increase levels of AEA (although not statistically enough compared to vehicle CUS) to 
where it could reduce CB1R genetic expression in URB597-treated CUS group compared 
to the vehicle CUS group in the PFC (Bortolato et al., 2007; Morena et al., 2016). This 
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speculation is supported by the significantly increased levels of AEA and PEA in the PFC 
by a 1 mg/kg dose of URB597 (Lomazzo et al., 2015).  
Surprisingly, URB597 at a dose of 0.3 and 1 mg/kg did not have any significant 
effect on AEA levels in the hippocampus compared to vehicle CUS groups (Bortolato et 
al., 2007; Lomazzo et al., 2015). Although there is one study reporting CUS-induced 
reductions of AEA levels and another reporting CUS-induced increases of FAAH protein 
expression, several studies did not find any significant effects of CUS on AEA levels or 
FAAH activity (Bortolato et al., 2007; Hill et al., 2005; Lomazzo et al., 2015; Morena et 
al., 2016). It is tempting to attribute the lack of significant effect of URB597 in the 
hippocampus to the former observations, but additional studies are needed to elucidate 
the effects of CBs in the hippocampus during CUS. On the other hand, JZL184 at a dose 
of 8 mg/kg significantly increases 2-AG levels in the cingulate, PFC, hypothalamus, 
midbrain, and hippocampus because it inhibits MAGL (Lomazzo et al., 2015). In the 
hippocampus, 2-AG levels are reduced by CUS (Hill et al., 2005; Morena et al., 2016). 
Therefore, it appears that in the hippocampus JZL184 has the ability to rescue this CUS-
induced reduction of 2-AG levels via inhibition of MAGL (the main catabolic enzyme for 
2-AG). The differences between the effects of CUS on 2-AG and AEA levels in the 
hippocampus requires further investigation.  
Stress-Related Effects 
 The most common stress-related biochemical measurements were focused on 
neuronal survival, growth, and synaptic plasticity. Five articles measured genetic and 
protein expression of brain derived neurotropic factor (BDNF). BDNF is important for 
neuronal survival, and its expression can be reduced by stress (Jin et al., 2015). In the 
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PFC, OEA and high levels of absorbed CBD significantly increase levels of BDNF in 
comparison to CUS vehicle groups (Jin et al., 2015; Xu et al., 2019). The effects of CBs 
on BDNF expression in the hippocampus are inconsistent which is likely due to the 
reduction of hippocampal volume observed in MDD (Franklin et al., 2012; Ulrich-Lai & 
Herman, 2009). All together these data suggest CBs that substantially enhance the ECS 
generally rescue CUS-induced decreases in BDNF expression and CBs which inhibit the 
ECS do not seem to rescue CUS-induced decreases in BDNF expression (García-
Gutiérrez et al., 2010; Hwang et al., 2020; Jin et al., 2015; H.-n. Wang et al., 2014; Xu et 
al., 2019). These data suggest that some CBs can be neuroprotective against CUS-
induced reductions in BDNF expression.  
For measuring neurogenesis, bromodeoxyuridine is neuronal marker for cell 
proliferation which can be combined with doublecortin and neuronal nuclear protein to 
identify immature and mature neurons, respectively (Fogaça et al., 2018). In the 
hippocampus, the effects of CBs on neuronal growth are inconsistent (Table 4). However, 
the proliferative effects of CBs appear to be mediated by CBs that substantially enhance 
the ECS, more specifically with increases in the eCB 2-AG and possibly through a CB2R 
mediated mechanism (Campos et al., 2013; Fogaça et al., 2018; H.-n. Wang et al., 2014; 
Zhang et al., 2015). Finally, within the hippocampus and in extended hippocampal 
projections to the nucleus accumbens, it appears that enhancing the ECS can increase 
measurements of long-term potential which is regarded as the strengthening of synaptic 
transmission (Segev et al., 2014; Zhang et al., 2015). 
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Cannabinoid Efficacy  
CB administration rescued the overall negative effects of CUS on anhedonia, 
learned helplessness, novelty suppressed feeding, and exploration anxiety with a pooled 
SMD of 0.4456 (95% CI 0.0498 – 0.8415, p = 0.0274) in comparison to the vehicle CUS 
group. The protective effects of CBs against CUS are significantly larger in mice, with 
CB treatments that are not co-treatments, with CBs that enhances the ECS, and with CBs 
administered during CUS. The effects of CBs in CUS also significantly increase with 
increased doses and administration frequencies. Therefore, future studies investigating 
the effects of CBs in CUS should reliably enhance the eCB tone during CUS. Based on 
these results, it would be interesting to investigate the therapeutic index of different CBs 
in CUS.  
 The protective effects of CBs were significantly greater in mice compared to rats, 
which supports previous findings that reported differences between rodent species on the 
effects of CBs in anxiety measurements (i.e. proportion of time and entries into open 
arms) in the elevated plus maze (Haller et al., 2007). In a study from Haller and 
colleagues, WIN55,212-2 (at a dose of 3 mg/kg in mice and 1 mg/kg in rats) was 
anxiolytic in mice and anxiogenic in rats (Haller et al., 2007). In this same study, AM251 
(at a dose of 3 mg/kg in mice and 5 mg/kg in rats) was anxiogenic in mice but had no 
effect on rats (Haller et al., 2007). In addition to differences between species, differences 
between mouse strains in both stress reactivity and effects of CB administration on 
anxiety behaviors have been reported (Franklin et al., 2012; Haller et al., 2007). Together 
these findings emphasize the influence of species and strains on stress-coping behaviors 
and highlight a need for further investigation.  
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In line with these findings, future research on the effect of CBs on rodent models 
of depression and anxiety in comparison to “control” models are needed. There is also a 
need for research on sex differences in the effects of CB in CUS. In the laboratory that 
included females in their research, one article conducted an open field test and the other 
an elevated plus maze and forced swim test (Ferizovic et al., 2020; Jankovic et al., 2020). 
In the elevated plus maze, CUS significantly reduced the percentage of entries into the 
anxiogenic context in both sexes and this reduction was greater in females (Jankovic et 
al., 2020). URB597 rescued CUS-induced reductions on the percentage of entries into the 
anxiogenic context in both sexes (Jankovic et al., 2020). Furthermore, CUS significantly 
reduced the time females spent in the anxiogenic context, but there were no significant 
effects in males or in URB597-treated CUS groups of either sex (Jankovic et al., 2020). 
In the open field test, URB597-treated CUS rats of both sexes rescued CUS-induced 
reductions in ambulation in anxiogenic context but the time spent in the anxiogenic was 
only rescued in males (Ferizovic et al., 2020). These data indicate that CUS-induced 
reductions in exploration anxiety are greater in females and that females respond 
differently to CB-based treatments when compared to males. It is possible that URB597 
only rescued time spent in the anxiogenic context in males because CUS-induced 
reductions in time spent in the anxiogenic context was greater in females (Ferizovic et al., 
2020; Jankovic et al., 2020). In the forced swim test, URB597-treated CUS rats of both 
sexes rescued CUS-induced increases in immobility time and this effect was greater in 
males (Jankovic et al., 2020). Similarly to exploration anxiety, the differences in 
treatment efficacy between sexes in the context of learned helplessness might be due to 
the increased effects of CUS-induced increase in immobility in females compared to 
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males. Regardless, the differences between sexes on the effect of CBs in CUS needs to be 
investigated further. Research on sex differences in CUS can be immensely impactful 
when considering the increased prevalence of stress-related psychopathologies in female 
humans and rodents compared to males (Franklin et al., 2012). Unfortunately, there were 
not enough effect sizes to be able to conduct the proposed moderator analyses for the 
effects of model (control vs. disease) and sex (males vs. females), which again highlights 
the need for the inclusion of these groups in future studies.    
Limitations 
Bias Assessment 
It is important to interpret the findings of this meta-analysis with caution as 
evaluation of these articles revealed that the most common modified SYRCLE’s risk of 
bias evaluation score across all measures (aside from the conflict of interest statement 
and vehicle administration) was “unclear” (Hooijmans et al., 2014). Based on these bias 
evaluations, it is important to not disregard the potential for bias in the included articles.  
Publication Bias and Heterogeneity 
An important limitation in meta-analysis research pertains to methodological 
heterogeneity. High heterogeneity of meta-analyses reduces the predictive validity of the 
meta-analysis results (Melsen, Bootsma, Rovers, & Bonten, 2014). Heterogeneity was 
quantified from #! in order to appropriately analyze and best interpret the predictive 
validity of the meta-analysis results (Higgins et al., 2003; Reade, Delaney, Bailey, & 
Angus, 2008). Although a random effects model was selected to best demonstrate the 
distribution of the studies estimated effects, results revealed moderate heterogeneity 
across studies (#!= 69.5218%) indicating inconsistent results (Melsen et al., 2014). The 
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most effective moderator in reducing heterogeneity was the time the drug was 
administered relative to CUS (#!= 56.6541%), which suggests that CBs have different 
efficacies depending on when they are administered in relation to stress.  
A second limitation in meta-analysis research that is especially prevalent in 
preclinical neuroscience research is small sample sizes, which reduces the reliability and 
validity of the studies’ outcomes (Button et al., 2013; Tipton, 2015). Small sample sizes 
can also lead to publication bias (Button et al., 2013; Reis et al., 2019). Therefore, the 
third limitation in this meta-analysis is publication bias, which weakens external validity 
of meta-analyses (Button et al., 2013; Reis et al., 2019). Publication bias funnel plots are 
assessed using Egger regression (Egger et al., 1997). An Egger regression was conducted 
on two versions of funnel plots (Figure 9 and Figure 10) in consideration to sample 
dependency. An Egger regression on the funnel plot of the full dataset (Figure 9) revealed 
the significant presence of asymmetry, whereas an Egger regression on the funnel plot of 
the subset data (Figure 10) approached the significant presence of asymmetry. Since the 
Egger regression on the funnel plot of the subset data approached the significant presence 
of asymmetry, these Egger regressions suggest that publication bias is present in this 
dataset. As previously stated, high heterogeneity and funnel plot asymmetry negatively 
affect meta-analyses as they weaken the external validity of the meta-analysis findings 
(Reis et al., 2019). Therefore, the interpretation of CB efficacy in stress-coping behaviors 
in CUS is limited by heterogeneity and publication bias and likely impacted by the small 
group sample sizes in the meta-analysis. In consideration of these limitations, the sources 
of heterogeneity and evaluation of biases still provide valuable guidance in improving the 
external validity of future studies. It is also important to note that a significant pooled 
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SMD despite moderate heterogeneity suggests that CBs are efficacious at rescuing the 
overall negative effects of CUS in a variety of context, therefore supporting the external 
validity of CB efficacy (Reade et al., 2008).  
In the interest of statistical power, the definition of the CUS paradigm was 
selected to be as inclusive as possible, and the most common stress-coping behavior tests 
were subjected to the meta-analysis. Although there were 70 measurement type studies 
across the five test measurements included in this meta-analysis, the statistical power of 
this considerably large number of studies was negatively impacted by heterogeneity, 
publication bias, and various levels of dependencies. Although the dependency was 
largely addressed with a multi-level mixed effects model and with effect size weights 
nested within control groups, attempts to elucidate sources heterogeneity and publication 
bias were less successful. It is possible that there are sources of methodological 
heterogeneity that were not reported in the articles thereby contributing to the limitations 
of meta-analysis research (Vesterinen et al., 2014). Fortunately, corresponding 
neuroendocrinological measurements, which were predicted to collect small aggregated 
samples, were indexed by brain region and systematically reviewed in order to contribute 
to a meaningful overview of the current literature. 
The final limitation is the search syntax which did not include all known CBs. 
The broadening of the search syntax from CUS to simply chronic stress increased the 
scope of the search and allowed all CUS paradigms to be included regardless or not if 
they used the specific keyword of CUS. The lack of additional articles found from the 
exploratory search on article recommendations provided by the Mendeley reference 
manager software, from contacting 53 researchers for grey literature, and from the 
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backwards and forwards citation tracking of the included articles, are all a testament in 
support of a comprehensive search strategy.  
  






What I Have Learned 
 
By conducting this meta-analysis, I have learned a tremendous amount about the 
realities of conducting neuroscience research. When facilitating collaboration, I have 
learned that there is a balance between allowing colleagues the opportunity to set their 
own deadlines and enforcing your own deadlines. I have also learned how valuable it is to 
plan in advance and in as much detail as possible to factor in plenty of buffer time in 
consideration of Murphy’s Law.  
With regards to realistic techniques to improve my own future research designs, I 
am committed to calculating the sample size using a formal power calculation rather than 
depending on historical precedent, and at the very least, I will report said sample size 
calculation in my published research (Button et al., 2013; Macleod et al., 2015). I will 
encourage myself to conduct a pre- and post-test, within-subject design as an additional 
control for the outcome measurements investigated or at the least conduct a preliminary 
study to screen for potential effects of a drug on the behavioral outcome that I am 
measuring. I will also be explicit about the contents of the vehicle solution when 
describing how the drug was prepared. I will ensure that I create counterbalanced groups 
and explicitly state as such (Hooijmans et al., 2014). I will report subjects’ sex, age, and 
weight and also control for the variance shared by littermates statistically by 
incorporating the mothers as a variable in the analysis (Hooijmans et al., 2014; Sequeira-
Cordero et al., 2019). For paradigms such as CUS, I will schedule my stressors no more 
than one week in advance to prevent myself from foreseeing intervention allocations 
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(Hooijmans et al., 2014). I will make sure to shuffle the shelf locations of my control and 
experimental groups and avoid labeling cages by group to prevent my own performance 
bias (Hooijmans et al., 2014). I will randomize the order of subjects being tested and their 
allocation to different types of analysis (Hooijmans et al., 2014). I will also implement 
means to blind both behavioral and biochemical analysis by asking a colleague to rename 
data folders that contain behavioral videos or biochemical images. I will report the initial 
group sizes, the group sizes for analysis, and explicitly state why any animals were 
removed or excluded from the study (Hooijmans et al., 2014). All data, including ones 
that are commonly not reported such as weight measurements, will be available in their 
entirety in the supplementary materials or on platforms such as the Open Science 
Framework. In addition, all tables used to generate figures and all analyses will be made 
publicly available. I will report effect sizes to facilitate future meta-analyses. I will also 
be fully transparent in the event that exploratory analyses are conducted or if any 
unanticipated changes occurred in the research process (Moreau & Gamble, 2020). 
Finally, I will ensure that my published research contains a conflict of interest statement 
(Macleod et al., 2015).  
Summary 
 The results of this current study comprehensively summarize the existing 
preclinical literature on the effect of CBs on stress-coping behaviors and 
neuroendocrinological measures in CUS. Despite revealing a significant pooled SMD in 
the model, the focus of this meta-analysis was to guide future preclinical study designs 
rather than evaluate the overall efficacy of CBs. These data highlight gaps in the 
literature by suggesting the sample characteristics for which such pharmacotherapies 
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should be preclinically tested and designed for. Furthermore, these data can help guide 
future preclinical research away from unnecessary replication of study designs and from 
studies which appear less efficacious (Vesterinen et al., 2014). Identifying the study 
designs which appear less efficacious will refocus research efforts towards preclinical 
studies that are more translationally impactful. Overall, these data provide a framework 
for the future direction of preclinical research investigating CB-based pharmacotherapies 
for stress-related psychopathologies. In alignment with the guidance this meta-analysis 
hopes to provide, the bias evaluation in this meta-analysis echoes the importance of 
reporting measurements which need to be taken to reduce the risk of bias in preclinical 
research in order to facilitate reproducible research and improve the external validity of 
preclinical research.  
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Date Description Rationale Impact 
10/27/2020 “Chronic unpredictable stress, defined 
as: #1 intermittent #2 heterotypic 
stressors at minimum #3 daily 
frequency occurring for over a #4 
week or longer“ criterion broadened to 
“Chronic stress (i.e. stress is 
administered for more than one day)” 
Increase the number of 
included articles with the type 




1/27/2021 Searched Mendeley reference manager 
suggested articles 
Relevant articles were being 
suggested and wanted to be 
systematically searched 
Addition to the 
search strategy 
2/13/2021 “Control group (i.e. vehicle 
administration)” criterion broadened to 
“Control group (i.e. vehicle 
administration) *Improper vehicles 
will be weighed less” 
Noticed articles administering 
multiple treatments did not 
use proper vehicles for each 
treatment 
Increased included 
articles that were 
weight adjusted 
2/1/2021 “Administration of a cannabinoid (e.g. 
WIN55,212-2) *Cotreatments will be 
weighed less” explicitly broadened to 
include acute administration 
Frequency of treatment was 
already planned to be 
addressed as a moderator in 




2/18/2021 “Chronic stress (i.e. stress is 
administered for more than one day)” 
criterion restricted to “Chronic 
Unpredictable Stress (i.e. variable 
stress is administered for more than 
seven days)” 
Was not feasible to examine 




3/3/2021 Excluded reviews were not backwards 
citation tracked 
Included articles that were 
backwards and forwards 
citation tracked did not yield 
any additional articles 
Removed from the 
initial search 
strategy 
3/15/21 Vehicle implemented in weight 
calculation 
Noticed articles which did not 
explicitly state the contents of 
their vehicle  
Reduces the weight 
of effect sizes in 
articles which did 
not use a proper 
control treatment 
3/22/21 Exploratory moderator analysis of 
time in learned helplessness meta-
analysis 
Check that the time of the test 




3/26/21 Co-treatments and vehicle addressed 
as a moderator and evaluation criteria, 
respectively 
Literature review did not 
provide a numeric value to 





Table 5. Protocol Deviations. Adapted from Moreau, D., & Gamble, B. (2020, January 
7). Conducting a Meta-Analysis in the Age of Open Science: Tools, Tips, and Practical 
Recommendations. https://doi.org/10.31234/osf.io/t5dwg 
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A. General  
1. Title of the review 
The Effect of Cannabinoids on Stress-Coping 
Behaviors and Neuroendocrinological 
Measures in Chronic Stress: A Preclinical 
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(Reviewer), and Schwartz S (Statistician). All 
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3. 
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Barrett T. (Statistician), Downs J. (Statistical 
Advice), and Culianos D (Statistical Advice). 
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4. 
Contact person + e-mail 
address 
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5. Funding sources/sponsors 
Utah State University’s College of Education 
& Human Services Graduate Student 
Research Award is funding Carlson’s work.  
 
6. Conflicts of interest None  
7. 
Date and location of 
protocol registration  
 
8. 




Stage of review at time of 
registration 
Conducted preliminary searches. McFarland 
conducted the Embase search (11/6/20). 
The remaining databases have not been 
searched yet.  
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 B. Objectives 
 Background 
10. 
What is already known 
about this 
disease/model/interventio
n? Why is it important to 
do this review? 
Substance use disorder (SUD) is one of 
many stress related psychiatric disorders 
(Bluett et al., 2017). Cannabinoids (CBs) 
demonstrate a biphasic effect on stress, 
with low doses being anxiolytic and high 
doses being anxiogenic (Scarante et al., 
2017). Due to the mounting evidence 
supporting endogenous CB’s fundamental 
role in regulating the hypothalamic pituitary 
adrenal (HPA) axis stress response, this 
project proposes to systematically review 
the current literature on the adverse and 
therapeutic effects of CBs on  stress-coping 
behaviors and neuroendocrinological 
measures (Hillard, Beatka, & Sarvaideo, 
2018). Elucidating the direction of future 
cannabinoid research is in line with 
reducing animal use, as defined in the 3Rs 
(Hooijmans, Tillema, Leenaars, & Ritskes-
Hoitinga, 2010). 
 
 Research question 
11. 
Specify the disease/health 
problem of interest 
Vulnerability to stress related psychiatric 









Chronic stress (i.e. stress is administered for 
more than one day).  
 
14. 
Specify the control 
population 
Within publication control (i.e. stress 
vehicle group). Robust variance estimation 
meta-regression will be used to address 
dependency between measurements in the 
same sample (Tipton, 2015). 
 
15. 
Specify the outcome 
measures 
Behavioural measures are organized into 
the following categories: elevated plus 
maze, elevated zero maze, elevated t maze, 
open field test, light-dark box test, hole 
board test, social interaction test, novelty 
suppressed feeding test, novelty induced 
hypophagia test, object recognition test, 
operant conflict test, fear conditioning, 
forced swim test, sucrose preference test, 
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acoustic startle response and prepulse 
inhibition, marble burying test. Examples of 
specific outcome measures include: 
weight lost, total distance travelled in 
meters, total time spent in anxiety context 
in seconds, total distance in anxiety context 
in meters, total distance in non-anxiety 
context in meters, total distance in 
between contexts in meters, total rearing 
time in seconds, total rearing frequency, 
total stretch attempt posture frequency, 
total grooming time in seconds, total 
grooming frequency, total digging time in 
seconds, total digging frequency, entries or 
crossing over to the anxiety context, total 
exploration time in seconds , latency to 
enter the anxiety context in seconds, total 
freezing time in seconds, freezing 
frequency, latency to approach food in 
seconds, % approached (approached 
test/total test), total sniffing time in 
seconds, total sniffing frequency, amount of 
food consumed in grams, familiar object 
exploration frequency, novel object 
exploration frequency, basal startle 
response amplitude, prepulse inhibition 
startle response amplitude, acoustic startle 
response latency in seconds, acoustic 
startle response amplitude, freezing 
behavior in seconds, ultrasonic 
vocalizations in kilohertz, raspatory 
frequency peak time in seconds, velocity 
(activity burst in meters / second, % 
unpunished responding 
(unpunished/baseline) % punished 
responding (punished/baseline), immobility 
time in seconds, swimming time in seconds, 
climbing time in seconds, sucrose intake, 
sucrose preference (sucrose intake/total 
fluid intake), and total number of marbles 
buried.    
Neuroendocrinological measures are 
organized into the following categories: 
organ weight, hormone concentrations, 
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genetic, chemical (i.e. Microdialysis), 
Assays, Histology, Blot, Post translational 
modifications, in situ hybridization, tract 
tracing, electrophysiology, and 
optogenetics. Example of a specific 
outcome: plasma corticosterone or 
adrenocorticotropic levels. 
16. 
State your research 
question (based on items 
11-15) 
Primary question: do cannabinoids have a 
protective or destructive effect on the HPA 
axis and complimentary stress-coping 
behaviors in the context of chronic stress? 
Secondary questions: does the type of 
stress, severity of stress, biological model, 
dosage, method of administration, timing of 
administration, and pharmacological effect 
influence the direction (protective or 
destructive) and efficacy of cannabinoids?  
 
 C. Methods 
 Search and study identification 
17. 
Identify literature 
databases to search (e.g. 
PubMed, Embase, Web of 
science) 
x MEDLINE via PubMed       □ Web of 
Science      
x  SCOPUS                               x EMBASE         
x Other, namely: Psychology and 
Behavioral Sciences Collection, APA 
PsychINFO, CINAHL Complete, and 
ProQuest Dissertations & Theses Global  
□Specific journal(s), namely:  
 
18. 
Define electronic search 
strategies (e.g. use the step 
by step search guide15 and 
animal search filters20, 21) 
(MICE) OR (RATS)  
AND  
(CHRONIC MILD STRESS) OR (CHRONIC 
UNPREDICTABLE STRESS) OR (CHRONIC 
VARIABLE STRESS) OR (CHRONIC 
HETEROTYPIC STRESS) OR (HETEROTYPIC 
STRESS) OR (CHRONIC STRESS) OR 
(CHRONIC HOMOTYPIC STRESS) OR 
(CHRONIC REPEATED STRESS) OR (CHRONIC 
PREDICTABLE STRESS) OR (STRESS COPING) 
OR (STRESS RESILIENCE) OR (STRESS 
VULNERABILITY) OR (HYPOTHALAMIC 
PITUITARY ADRENAL) OR (HYPOTHALAMIC 
PITUITARY ADRENAL AXIS) OR 
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(CORTICOTROPIN RELEASING HORMONE) 
OR (CORTICOTROPIN RELEASING FACTOR) 
OR (CORTICOSTERONE) OR 
(ADRENOCORTICOTROPIC HORMONE) 
AND 
(CANNABINOID RECEPTOR) OR 
(CANNABINOID 1 RECEPTOR) OR 
(CANNABINOID 2 RECEPTOR) OR (CB1 
CANNABINOID RECEPTORS) OR (CB2 
CANNABINOID RECEPTORS) OR (CANNABIS) 
OR (CANNABIS SATIVA) OR 
(TETRAHYDROCANNABINOL) OR 
(TETRAHYDROCANNABINOLIC ACID) OR 
(CANNABINOID) OR (CANNABINOIDS) OR 
(MARIJUANA) OR (CANNABIDIOL) OR 
(CANNABINOL) OR (DRONABINOL) OR 
(MARINOL) OR (NABILONE) OR (CESAMET) 
OR (ANANDAMIDE) OR 
(ARACHIDONOYLGLYCEROL) OR 
(RIMONABANT) OR (SR141716) OR (FATTY 
ACID AMIDE HYDROLASE) OR (NABIXIMOLS) 
OR (ACYLGLYCEROL LIPASE) OR (WIN55 212 
2) OR (WIN55212 2) OR (EXOGENOUS 
CANNABINOIDS) OR (SYNTHETIC 
CANNABINOIDS) OR (ARACHIDONOYL 
ETHANOLAMIDE) 
*full syntax search provided at the end of 
the protocol 
19. 
Identify other sources for 
study identification  
x  Reference lists of included studies           
□Books  
x    Reference lists of relevant reviews 
□Conference proceedings, namely: 
x  Contacting authors/ organisations, 
namely: Authors of included studies, the 
National Institute of Health, and the 
Hebrew University Multidisciplinary Center 




Define search strategy for 
these other sources 
Forward tracking of the citations of 
included studies will be conducted using 
Google Scholar’s “cited by” feature for 
newer literature.  
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 Study selection 
21. 
Define screening phases 
(e.g. pre-screening based 
on title/abstract, full text 
screening, both) 
First phase: title and abstract 
Second phase: full text screening  
 
22. 
Specify (a) the number of 
reviewers per screening 
phase and (b) how 
discrepancies will be 
resolved 
(a) Two independent researchers will 
conduct both screening phases. (b) 
Discrepancies will be resolved by discussion 
with the reviewer (third independent 
researcher) that will make the final 
decision. 
 
 Define all inclusion and exclusion criteria based on: 
23. Type of study (design) 
Inclusion criteria: within the study there is a 
control group receiving stress and vehicle 
administration 
Exclusion criteria: no control group 
 
24. 
Type of animals/population 
(e.g. age, gender, disease 
model) 
Inclusion criteria: mice or rats 
Exclusion criteria: not mice nor rats 
 
25. 
Type of intervention (e.g. 
dosage, timing, frequency) 
Inclusion criteria: repeated administration 
of any cannabinoid at any dosage at any 
time and at any frequency relative to the 
stress paradigm (administration of a 
cannabinoid with another non-cannabinoid 
compound will also be included and the 
study will be statistically weighed less in 
order to take the effects of the other 
compound into consideration) 
Exclusion criteria: cannabinoid is only 
administered once 
 
26. Outcome measures 
Inclusion criteria: Stress coping behaviors 
and/or 
Neuroendocrinological measures 
Exclusion criteria: no measures related to 
stress 
 
27. Language restrictions 
Inclusion criteria: English references 
Exclusion criteria:  non-English references  
Although this criteria poses as an inherent 
bias against non-English references, there 
appears to be minimal benefit in the 
translation of non-English references (Jüni, 
Holenstein, Sterne, Bartlett, & Egger, 2002) 
 





Inclusion criteria: Oldest studies to 
November 2020 
Exclusion criteria: none 
 
29. Other 
Inclusion criteria: primary source peer 
reviewed article and unpublished data 
Exclusion criteria: secondary sources (e.g. 
reviews) and conference abstracts due to 
lack of readily available data 
Inclusion criteria: chronic stress (i.e. stress 
is administered for more than one day) 
Exclusion criteria: only one day of stress  
 
30. 
Sort and prioritize your 
exclusion criteria per 
selection phase 
Title/abstract phase:  
1. Article text available in English  
2. Subjects are rats or mice 
3. Administration of a cannabinoid 
(e.g. WIN55,212-2) *Cotreatments 
will be weighed less 
4. Outcome data related to anxiety 
tests (e.g. Open Field test) or stress-
coping behaviors (e.g. Self-
Grooming) and/or accompanying 
biochemical data (e.g. related to the 
endogenous cannabinoid system or 
hypothalamic pituitary adrenal axis 
stress response) 
5. Chronic stress (i.e. stress is 
administered for more than one 
day). 
6. Control group (i.e. vehicle 
administration) 
7. Primary Research 
 
Full-text phase: 
1. Article text available in English  
2. Subjects are rats or mice 
3. Administration of a cannabinoid 
(e.g. WIN55,212-2) *Cotreatments 
will be weighed less 
4. Outcome data related to anxiety 
tests (e.g. Open Field test) or stress-
coping behaviors (e.g. Self-
Grooming) and/or accompanying 
biochemical data (e.g. related to the 
endogenous cannabinoid system or 
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hypothalamic pituitary adrenal axis 
stress response) 
5. Chronic stress (i.e. stress is 
administered for more than one 
day). 
6. Control group (i.e. vehicle 
administration) 
7. Primary Research 
 
Study characteristics to be extracted (for assessment of external validity, reporting 
quality) 
**full proposed codebook available on the Open Science Framework  
DOI 10.17605/OSF.IO/CSGMF 
31. 
Study ID (e.g. authors, 
year) 
- Authors (chr) 
- Year (num)  






number of animals) 
- Number of experimental groups 
(num) 
- Number of animals per group 
(num) 
- Total animals (num) 
- Enrichment (fct) 
- Handling frequency per day 
(num) 
- Handling duration in days (num) 
- Food and water regimen (chr) 
- Light cycle (chr) 
- Temperature of the 
experimental room or condition 
(e.g. water bath in forced swim 
test) (num) 
- Duration of housing in days 
(num) 
- Time of day (fct) 





species, gender, disease 
induction) 
- Strain (chr) 
- Sex (fct) 
- Age in days (num) 
- Single/group housing (fct) 





(e.g. intervention, timing, 
duration) 
- Number of different stressors 
(num) 
- Intensity of stressors (fct) 
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- Average frequency of stressors 
per day (num) 
- Disrupting circadian rhythm (fct) 
- Size of chamber (chr) 
- Dosage in mg/kg (num) 
- Timing of injection in hours 
relative to paradigm (chr) 
- Solvent (chr) 
- Vehicle information (chr) 
- Cannabinoid (chr) 
35. Outcome measures 
- Mean acoustic startle response 
in seconds (num) 
- Latency to enter the 
room/eat/engage with novel 
stimulus in seconds (num) 
- Percentage of time spent in 
elevated/open arms (num) 
- Mean grooming behavior in licks 
(num) 
- Forced swim immobility time in 
seconds (num) 
- Digging behaviour in seconds 
(num) 
 
36. Other (e.g. drop-outs) 
Please see the full proposed codebook 
available on the Open Science Framework  
DOI 10.17605/OSF.IO/CSGMF 
 
 Assessment risk of bias (internal validity) or study quality 
37. 
Specify (a) the number of 
reviewers assessing the risk 
of bias/study quality in 
each study and (b) how 
discrepancies will be 
resolved 
(a) Two independent researchers will 
independently assess the risk of bias. (b) 
Discrepancies will be resolved by discussion 
with the reviewer (third independent 




Define criteria to assess (a) 
the internal validity of 
included studies (e.g. 
selection, performance, 
detection and attrition 
bias) and/or (b) other study 
quality measures (e.g. 
reporting quality, power) 
□By use of SYRCLE's Risk of Bias tool4  
x  By use of SYRCLE’s Risk of Bias tool, 
adapted as follows:  adding control for 
locomotor effects, conflicts of interest, and 
sample size calculations to the evaluation 
□By use of CAMARADES' study quality 
checklist, e.g 22  
□By use of CAMARADES' study quality 
checklist, adapted as follows:   
□Other criteria, namely: 
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 Collection of outcome data 
39. 
For each outcome 
measure, define the type 
of data to be extracted 
(e.g. 
continuous/dichotomous, 
unit of measurement) 
Please see the full proposed codebook 




Methods for data 
extraction/retrieval (e.g. 
first extraction from graphs 
using a digital screen ruler, 
then contacting authors) 
The data is extracted from graphs, if 
applicable, using WebPlotDigitizer. The 
original authors will be also be contacted to 
request the raw data.   
 
41. 
Specify (a) the number of 
reviewers extracting data 
and (b) how discrepancies 
will be resolved 
(a) Two independent researchers will 
independently extract the data. (b) 
Discrepancies will be resolved by discussion 
with the reviewer (third independent 
researcher) that will make the final 
decision. 
 
 Data analysis/synthesis 
42. 
Specify (per outcome 
measure) how you are 
planning to 
combine/compare the data 
(e.g. descriptive summary, 
meta-analysis) 
Stress coping behaviors with continuous 
measures will be combined through meta-
analysis. 
Neuroendocrinological measures will be 
combined onto a table with a descriptive 
summary for each study. 
 
43. 
Specify (per outcome 
measure) how it will be 
decided whether a meta-
analysis will be performed 
Meta-analysis will be carried out if there is 
sufficient replicated studies (#>3) looking at 
equivalent outcomes.  
 
 If a meta-analysis seems feasible/sensible, specify (for each outcome measure): 
44. 
The effect measure to be 
used (e.g. mean difference, 
standardized mean 
difference, risk ratio, odds 
ratio) 
Standardized mean difference will be used 




The statistical model of 
analysis (e.g. random or 
fixed effects model) 
Random effects model will be performed 
because it assumes distribution of the 
studies estimated effects (Melsen, 
Bootsma, Rovers, & Bonten, 2014).   
 
46. 
The statistical methods to 
assess heterogeneity (e.g. 
I2, Q) 
Between- study heterogeneity will be 
evaluated using the #!	statistic with #!more 
than 25%, 50%, and 75% selected to reflect 
low, moderate, and high heterogeneity 
 























respectively (Higgins, Thompson, Deeks, & 
Altman, 2003). 
47. 
Which study characteristics 
will be examined as 
potential source of 
heterogeneity (subgroup 
analysis) 
Species (rats vs mice), type of stress 
(heterotypic vs homotypic), dosage, timing 
of administration relative to stress, 
biological model, frequency of treatment, 
treatment pharmacology, severity of stress, 
method of administration, and 
pharmacological effect (e.g. agonist) 
 
48. 
Any sensitivity analyses 
you propose to perform 
A sensitivity analysis with the high risk-of-
bias studies removed may be performed. 
 
49. 
Other details meta-analysis 
(e.g. correction for multiple 
testing, correction for 
multiple use of control 
group) 
Correction for multiple use of control group 
will be addressed using robust variance 
estimation meta-regression (Tipton, 2015). 
 
50. 
The method for 
assessment of publication 
bias 
Publication bias funnel plots will be 
assessed using Egger regression and 
corrected for using trim and fill if possible 
(Egger, Smith, Schneider, & Minder, 1997; 
Vesterinen et al., 2014). 
 
 
Final approval by (names, 
affiliations):  
 Date:  
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Search Syntax (ROW #1 AND ROW #2 AND ROW 
#3) 
Conducte
d by  
1. Scopus 
(Elsevier)  




( TITLE-ABS-KEY ( {CHRONIC MILD STRESS} OR 
{CHRONIC UNPREDICTABLE STRESS} OR 
{CHRONIC VARIABLE STRESS} OR {CHRONIC 
HETEROTYPIC STRESS} OR {HETEROTYPIC 
STRESS} OR {CHRONIC STRESS} OR {CHRONIC 
HOMOTYPIC STRESS} OR {CHRONIC REPEATED 
STRESS} OR {CHRONIC PREDICTABLE 
STRESS} OR {STRESS COPING} OR {STRESS 
RESILIENCE} OR {STRESS VULNERABILITY} OR 
{HYPOTHALAMIC PITUITARY ADRENAL} OR 
{HYPOTHALAMIC PITUITARY ADRENAL AXIS} 
OR {CORTICOTROPIN RELEASING HORMONE} OR 
{CORTICOTROPIN RELEASING FACTOR} OR 
{CORTICOSTERONE} OR {ADRENOCORTICOTROP
IC HORMONE} ) ) 
( TITLE-ABS-KEY ( {CANNABINOID RECEPTOR} 
OR {CANNABINOID 1 RECEPTOR} OR 
{CANNABINOID 2 RECEPTOR} OR {CB1 
CANNABINOID RECEPTORS} OR {CB2 
CANNABINOID RECEPTORS} OR {CANNABIS} OR 
{CANNABIS SATIVA} OR 
{TETRAHYDROCANNABINOL} OR 
{TETRAHYDROCANNABINOLIC ACID} OR 
{CANNABINOID} OR {CANNABINOIDS} OR 
{MARIJUANA} OR {CANNABIDIOL} OR 
{CANNABINOL} OR {DRONABINOL} OR 
{MARINOL} OR {NABILONE} OR {CESAMET} OR 
{ANANDAMIDE} OR 
{ARACHIDONOYLGLYCEROL} OR 
{RIMONABANT} OR {SR141716} OR {FATTY ACID 
AMIDE HYDROLASE} OR {NABIXIMOLS} 
OR {ACYLGLYCEROL LIPASE} OR {WIN55 212 2} 
OR {WIN55212 2} OR {EXOGENOUS 
CANNABINOIDS} OR {SYNTHETIC 
CANNABINOIDS} OR {ARACHIDONOYL 
ETHANOLAMIDE} ) ) 
2. Embase 
(Elsevier) 
#16 #15 NOT 'conference abstract'/it   430 [Final set] 
#15 #13 AND #14  517 
#14 'mouse'/exp OR 'rat'/exp OR mouse:ti,ab,kw OR 
mice:ti,ab,kw OR mus:ti,ab,kw OR rat:ti,ab,kw OR 
rats:ti,ab,kw OR rattus:ti,ab,kw   [Rat,mouse 
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#13 #7 AND #12   1140 Cannabinoids + Chronic 
stress/HPA set]   
#12 #8 OR #9 OR #10 OR #11  Chronic stress/HPA 
set]      164056 
#11 'hypothalamic pituitary adrenal':ti,ab,kw OR 
'hypothalamic pituitary adrenal axis':ti,ab,kw OR 
'corticotropin releasing hormone':ti,ab,kw OR 
'corticotropin releasing factor':ti,ab,kw OR 
'corticosterone':ti,ab,kw OR 'adrenocorticotropic 
hormone':ti,ab,kw   63105 
#10 'corticotropin releasing factor'/de OR 'cortisone'/de 
OR 'corticotropin'/de   108652 
#9 'chronic mild stress':ti,ab,kw OR 'chronic 
unpredictable stress':ti,ab,kw OR 'chronic variable 
stress':ti,ab,kw OR 'chronic heterotypic stress':ti,ab,kw 
OR 'heterotypic stress':ti,ab,kw OR 'chronic 
stress':ti,ab,kw OR 'chronic homotypic stress':ti,ab,kw OR 
'chronic repeated stress':ti,ab,kw OR 'chronic predictable 
stress':ti,ab,kw OR 'stress coping':ti,ab,kw OR 'stress 
resilience':ti,ab,kw OR 'stress vulnerability':ti,ab,kw   
 18292 
#8 'chronic stress'/de OR 'chronic unpredictable 
stress'/de   10876 
#7 #3 OR #6   [cannabinoids/receptors set]  
 90701 
#6 #4 OR #5   [cannabinoid receptor set]  
 18339 
#5 (receptor* NEAR/2 (cannabinoid* OR 
tetrahydrocannabinol*)):ti,ab,kw   12814 
#4 'cannabinoid receptor'/de OR 'cannabinoid 1 
receptor'/de OR 'cannabinoid 2 receptor'/de   
 14990 
#3 #1 OR #2   89637 [cannabinoids set]   
#2 'cannabis':ti,ab,kw OR 'cannabis sativa':ti,ab,kw 
OR 'tetrahydrocannabinol':ti,ab,kw OR 
'tetrahydrocannabinolic acid':ti,ab,kw OR 
'cannabinoid':ti,ab,kw OR 'cannabinoids':ti,ab,kw OR 
'marijuana':ti,ab,kw OR 'cannabidiol':ti,ab,kw OR 
'cannabinol':ti,ab,kw OR 'dronabinol':ti,ab,kw OR 
'marinol':ti,ab,kw OR 'nabilone':ti,ab,kw OR 
'cesamet':ti,ab,kw OR 'anandamide':ti,ab,kw OR 
'arachidonoylglycerol':ti,ab,kw OR 'rimonabant':ti,ab,kw 
OR 'sr141716':ti,ab,kw OR 'fatty acid amide 
hydrolase':ti,ab,kw OR 'nabiximols':ti,ab,kw OR 
'acylglycerol lipase':ti,ab,kw OR 'win55 212 2':ti,ab,kw 
OR 'win55212 2':ti,ab,kw OR 'exogenous 
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cannabinoids':ti,ab,kw OR 'synthetic 
cannabinoids':ti,ab,kw OR 'arachidonoyl 
ethanolamide':ti,ab,kw    68172 





























(CHRONIC MILD STRESS) OR (CHRONIC 
UNPREDICTABLE STRESS) OR (CHRONIC 
VARIABLE STRESS) OR (CHRONIC HETEROTYPIC 
STRESS) OR (HETEROTYPIC STRESS) OR 
(CHRONIC STRESS) OR (CHRONIC HOMOTYPIC 
STRESS) OR (CHRONIC REPEATED STRESS) OR 
(CHRONIC PREDICTABLE STRESS) OR (STRESS 
COPING) OR (STRESS RESILIENCE) OR (STRESS 
VULNERABILITY) OR (HYPOTHALAMIC 
PITUITARY ADRENAL) OR (HYPOTHALAMIC 
PITUITARY ADRENAL AXIS) OR 
(CORTICOTROPIN RELEASING HORMONE) OR 
(CORTICOTROPIN RELEASING FACTOR) OR 
(CORTICOSTERONE) OR 
(ADRENOCORTICOTROPIC HORMONE) 
(CANNABINOID RECEPTOR) OR (CANNABINOID 1 
RECEPTOR) OR (CANNABINOID 2 RECEPTOR) OR 
(CB1 CANNABINOID RECEPTORS) OR (CB2 
CANNABINOID RECEPTORS) OR (CANNABIS) OR 
(CANNABIS SATIVA) OR 
(TETRAHYDROCANNABINOL) OR 
(TETRAHYDROCANNABINOLIC ACID) OR 
(CANNABINOID) OR (CANNABINOIDS) OR 
(MARIJUANA) OR (CANNABIDIOL) OR 
(CANNABINOL) OR (DRONABINOL) OR 
(MARINOL) OR (NABILONE) OR (CESAMET) OR 
(ANANDAMIDE) OR 
(ARACHIDONOYLGLYCEROL) OR (RIMONABANT) 
OR (SR141716) OR (FATTY ACID AMIDE 
HYDROLASE) OR (NABIXIMOLS) OR 
(ACYLGLYCEROL LIPASE) OR (WIN55 212 2) OR 
(WIN55212 2) OR (EXOGENOUS CANNABINOIDS) 











noft("CHRONIC MILD STRESS" OR "CHRONIC 
UNPREDICTABLE STRESS" OR "CHRONIC 
VARIABLE STRESS" OR "CHRONIC HETEROTYPIC 
STRESS" OR "HETEROTYPIC STRESS" OR 
“CHRONIC STRESS” OR “CHRONIC HOMOTYPIC 
STRESS” OR “CHRONIC REPEATED STRESS” OR 
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“CHRONIC PREDICTABLE STRESS” OR "STRESS 
COPING" OR "STRESS RESILIENCE" OR "STRESS 
VULNERABILITY" OR "HYPOTHALAMIC 
PITUITARY ADRENAL" OR "HYPOTHALAMIC 
PITUITARY ADRENAL AXIS" OR 
"CORTICOTROPIN RELEASING HORMONE" OR 
"CORTICOTROPIN RELEASING FACTOR" OR 
"CORTICOSTERONE" OR 
"ADRENOCORTICOTROPIC HORMONE") 
noft("CANNABINOID RECEPTOR" OR 
"CANNABINOID 1 RECEPTOR" OR "CANNABINOID 
2 RECEPTOR" OR "CB1 CANNABINOID 
RECEPTORS" OR "CB2 CANNABINOID 
RECEPTORS" OR "CANNABIS" OR "CANNABIS 
SATIVA" OR "TETRAHYDROCANNABINOL" OR 
"TETRAHYDROCANNABINOLIC ACID" OR 
"CANNABINOID" OR "CANNABINOIDS" OR 
"MARIJUANA" OR "CANNABIDIOL" OR 
"CANNABINOL" OR "DRONABINOL" OR 
"MARINOL" OR "NABILONE" OR "CESAMET" OR 
"ANANDAMIDE" OR 
"ARACHIDONOYLGLYCEROL" OR 
"RIMONABANT" OR "SR141716" OR "FATTY ACID 
AMIDE HYDROLASE" OR "NABIXIMOLS" OR 
"ACYLGLYCEROL LIPASE" OR "WIN55 212 2" OR 
"WIN55212 2" OR "EXOGENOUS CANNABINOIDS" 
OR "SYNTHETIC CANNABINOIDS" OR 
"ARACHIDONOYL ETHANOLAMIDE") 
Table 6. Search Terms. Adapted from Moreau, D., & Gamble, B. (2020, January 7). 
Conducting a Meta-Analysis in the Age of Open Science: Tools, Tips, and Practical 
Recommendations. https://doi.org/10.31234/osf.io/t5dwg 
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ID Lab Species  Stress_Days High_num Bias 
Bortolato (2007) 1 Rats 70 2 3 
Buran (2017) 2 Mice 49 2 2 
Campos (2013) 3 Mice 14 2 4 
Fang (2018) 4 Rats 21 0 7 
Ferizovic (2020) 5 Rats 42 0 4 
Fogaca (2018) 3 Mice 14 3 2 
Fokos (2010) 6 Rats 10 0 5 
Gall (2020) 7 Rats 28 0 8 
Garcia Gutierrez (2010) 8 Mice 49 1 7 
Griebel (2005) 9 Mice 49 2 1 
Hill (2004) 10 Rats 21 0 5 
Hwang (2020) 11 Rats 28 0 5 
Ishiguro (2018) 12 Mice 14 0 6 
Jankovic (2020) 5 Rats 42 0 4 
Jin (2015) 13 Mice 28 1 6 
Lomazzo (2015) 14 Mice 73 0 4 
Lomazzo (2017) 14 Mice 73 0 4 
McLaughlin (2013) 10 Rats 21 0 9 
Onaivi (2008) 12 Mice 28 4 0 
Pekala (2018) 15 Mice 27 0 5 
Segev (2014) 16 Rats 21 1 4 
Wang (2014) 17 Rats 28 0 6 
Wang (2016) 18 Rats 18 1 3 
Xu (2019) 19 Mice 35 0 4 
Zhang (2015) 20 Mice 35 0 6 
Zhong (2014) 20 Mice 35 0 4 
 
Table 7. Article Moderators. Article level moderators that were imported into R for 
analysis. For the full datasets, including study-level moderators, please visit the Open 
Science Framework (https://osf.io/csgmf/). ID – article identification, Stress_days – 
number of days of stress, High_num, number of “high” evaluation scores, Bias – 
calculated bias score. 
